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ABSTRACT 
PROTEIN-NANOPARTICLE CO-ENGINEERING: SELF-
ASSEMBLY, INTRACELLULAR PROTEIN DELIVERY, AND 
CRISPR/CAS9-BASED GENE EDITING 
 
SEPTEMBER 2017 
RUBUL MOUT 
B.Sc., TINSUKIA COLLEGE, DIBRUGARGH UNIVERSITY 
M.Sc., GAUHATI UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
 
Direct cytoplasmic delivery of gene editing nucleases such CRISPR/Cas9 systems 
and therapeutic proteins provides enormous opportunities in curing human genetic 
diseases, and assist research in basic cell biology. One approach to attain such a goal is 
through engineering nanotechnological tools to mimic naturally existing intra- and 
extracellular protein delivery/transport systems. Nature builds transport systems for 
proteins and other biomolecules through evolution-derived sophisticated molecular 
engineering. Inspired by such natural assemblies, I employed molecular engineering 
approaches to fabricate self-assembled nanostructures to use as intracellular protein 
delivery tools. Briefly, proteins and gold nanoparticles were co-engineered to carry 
complementary electrostatic recognition elements. When these materials were mixed 
together, they formed highly sophisticated, multi-layered, and hierarchical self-assembled 
nanostructures of few hundred-nanometer size. These structures carried a large number of 
viii 
 
engineered proteins, got fused to cell membrane upon incubation, and delivered the 
encapsulated protein content directly into cell cytoplasm. Using this technology, we 
delivered a wide range of proteins, and CRISPR/Cas9-ribonucleoprotein that resulted high 
efficient gene editing.  
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CHAPTER 1 
NANOTECHNOLOGY FOR THERAPEUTIC PROTEIN AND 
CRISPR/CAS9 DELIVERY 
 
 
1.1. Protein therapeutics and challenges in intracellular protein delivery 
There are approximately 10,000 human diseases of which only 500 have any cure, 
according to an information provided by National Institute of Health (NIH).1 In the past 
century and so, small molecule therapeutics have revolutionized human medicine curing 
many major diseases.2 Most of the small molecule therapeutics target endogenous proteins, 
resulting in perturbation or activation of protein functions.3 However, as indicated by NIH 
information, we are still far away from the complete curing of human diseases.  
In 1922, at the beginning of twentieth century protein was directly used as 
therapeutics for the first time. A Canadian surgeon, Dr. Frederick Banting, and his 
associates isolated insulin from cows and injected into human patients to cure hitherto 
incurable Diabetes.4 It was the beginning of a new class of therapeutics, named ‘biological 
therapeutics’ or ‘biologics’ or ‘biopharmaceuticals’.5 The idea was to use biological large 
molecules such as proteins, DNA, and RNA directly to cure various diseases. Although 
promising, this class of therapeutics had very limited success in the last 95 years. Despite 
a tremendous effort to use biologics to cure human diseases, only 246 such therapeutics 
have been approved worldwide till 2014.5 Among these, most of the protein therapeutics 
function in blood or extracellularly in tissues. For example, while insulin, monoclonal 
antibodies, and growth hormones bind to cell surface receptor for their therapeutic effect, 
blood factors, anticoagulants and thrombolytics function in the blood. Only a small number 
2 
 
of these protein therapies (10 out of 246) work as intracellular therapy (Figure 1.1). 
Interestingly, all these 10 intracellular protein therapies are used as enzyme replacement 
therapy for lysosomal disorders. No approved protein therapies have crossed 
endo/lysosomal barrier so far to reach other intracellular organelles. 
 
Figure 1. 1. Protein therapeutics. A) Out of 246 biopharmaceuticals approved so far, only 10 (4%) 
work intracellularly. B) Delivered protein therapeutics get trapped in the endosomes, and thus no 
protein therapeutics have been approved so far that have the capability to cross the endo/lysosomal 
barrier. 
 
Designing vehicles to deliver therapeutic proteins that can escape the 
endo/lysosomal barrier have been a long-standing goal in biomedical research.6 A search 
in ‘Pubmed’ or ‘Scifinder’ with a key phrase ‘intracellular protein delivery’ shows 6,000-
11,000 published research articles, indicating an enormous number of ongoing research 
activities towards designing better intracellular protein delivery methods. Despite such 
efforts, majority of these delivery strategies suffer from endosomal entrapment of cargos 
that ultimately undergo degradation.7 Only a small fraction of the entrapped protein cargo 
(~1%) escape from the endosomes, making these strategies highly inefficient.8 
There have been three broad categories of intracellular protein delivery strategies: 
a carrier based delivery method, covalent modification of cargo proteins, and mechanical 
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methods.6 Carrier based protein delivery methods employ various nanocarriers such as 
polymers, lipid and inorganic nanoparticles to transport proteins across cell membranes.9 
Protein cargos can also be covalently modified with different cell penetrating peptides and 
proteins providing a carrier-free delivery approach.10 However, both of these strategies 
suffer from endosomal entrapment of cargos, a major drawback that hinders the ultimate 
use of these approaches for therapeutic intracellular protein delivery.9 Mechanical 
distortion methods such as electroporation11 and microneedle injection12 can achieve 
efficient cytoplasmic protein delivery, however these techniques are disruptive and less 
practical for in vivo therapeutic applications.7 
Recently, our laboratory engineered a nanocarrier system to deliver proteins 
directly into cell cytoplasm, thus avoiding cellular endocytosis.13-15 In our system, arginine 
functionalized gold nanoparticles and native proteins self-assembled on the surface of oil 
droplets to form Nanoparticle-stabilized capsules (NPSCs).16 These NPSCs provided a 
strategy for high efficient direct cytoplasmic protein delivery, however, limited to proteins 
that have native pI values below 7.0.17 Therefore, a general strategy that can deliver any 
protein directly in to cell cytosol, and avoiding endosomal entrapment, is in great demand 
for protein therapeutics.  
 
1.2. CRISPR/Cas9 delivery for therapeutic gene editing 
Off 10,000 human diseases reported by NIH, many thousand diseases are caused 
by genetic alterations in the human genome.1 Therefore, a more practical approach to cure 
these diseases is by fixing the altered gene itself, rather than delivering a functional protein 
to replace the abnormal protein. Recently invented gene editing technology CRISPR/Cas9 
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systems (Clustered Regularly Interspaced Short Palindromic Repeat) to manipulate 
mammalian genomes presents enormous opportunities for curing human diseases.18-20 
CRISPR technology enables correcting such genetic alterations, making a large number of 
these diseases therapeutic targets. 
Bacterial CRISPR/Cas9 system is composed of two elements: a nuclease protein 
Cas9 that cuts double-stranded DNA, and a guide RNA molecule (sgRNA) that guides the 
Cas9 protein to a specific DNA sequence (Figure 1.2).21-25 This system (Cas9 protein and 
the sgRNA, together called CRISPR/Cas9) has been harnessed in mammalian cells to 
specifically cut target genes, followed by repairing of the target gene via host cell repair 
machinery. The repair can occur through two main mechanisms.26 (1) Non-Homologous 
End Joining (NHEJ): this mechanism allows the cell to randomly insert or delete 
nucleotides at the CRISPR-mediated double-stranded DNA break site, resulting in gene 
coding sequence disruption. (2) Homology-Directed Repair (HDR):  this mechanism 
provides insertion of a template DNA to correct mutations at the DNA break site.  
For therapeutic use the CRISPR components need to be delivered into mammalian 
cells to enable gene modification in the host cell. Once delivered, the CRISPR/Cas9 system 
can manipulate host cell genome in numerous ways. Depending on the desired genetic 
manipulation, various components of CRISPR/Cas9 are delivered: (a) a minimal 
Cas9/sgRNA pair for gene disruption/mutation, (b) Cas9/sgRNA, and a ‘spare’ template 
DNA for gene correction, (c) Cas9/sgRNA, and a desired gene for gene insertion, and (d) 
Cas9 and two sgRNAs for the complete deletion of a gene (or a portion of a gene) (Figure 
1.2). In its simplest implementation Cas9/sgRNA pair is sufficient for gene disruption (i.e. 
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knockout), however, the delivery of an additional piece of DNA is required for advanced 
functions such as gene repair or insertion (knock-in).  
 
Figure 1. 2. CRISPR delivery strategies. Multiple components of CRISPR/Cas9 system are 
delivered into cells to achieve a specific function. (a) Cas9 and sgRNA for gene disruption (knock-
out), (b) Cas9, sgRNA, and a template ssDNA for mutation correction, (c) Cas9, sgRNA, and a 
template DNA for gene insertion (knock-in), and (d) Cas9 and two sgRNAs for gene deletion. 27 
 
In addition, the CRISPR/Cas9 components can be delivered into cells in different 
formats: plasmids or viral vectors that carrying Cas9 and sgRNA genes in gene-based 
delivery; Cas9 mRNA and a synthetic sgRNA in RNA-based delivery; Cas9 protein and a 
synthetic sgRNA in protein-based delivery (Table 1.1).28 Thus far, Cas9 protein delivery 
has many advantages over gene or RNA delivery methods. Protein delivery is transient and 
therefore is less immunogenic. Moreover, unlike gene delivery, protein delivery does not 
have the issue of permanently integrating CRISPR genes into the host genome (Table 1.1). 
Although a number of CRISPR delivery platform has been designed so far, the effective 
delivery of multiple CRISPR components in vivo into host cells still remains a major 
challenge.   
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Table 1.1. Comparison, and pros/cons of CRISPR/Cas9 delivery in different formats. Compared 
to other format of delivery, Cas9-RNP delivery has the most advantage as it offers no insertional 
mutagenesis, high editing efficiency, low off-target, and low immunogenicity.27 
 
  
 
1.3. Current CRISPR/Cas9 delivery strategies 
A wide variety of intracellular delivery vehicles for CRISPR/Cas9 has been 
designed so far, intending to deliver CRISPR components in all formats described above. 
Broadly, the delivery vehicles can be classified into viral and non-viral.28 Non-viral 
vehicles can be further classified into synthetic and mechanical methods. Viral delivery 
methods are usually restricted to CRISPR gene delivery, whereas non-viral methods can 
deliver CRISPR in the form of plasmid DNA, Cas9 mRNA or Cas9 protein along with in 
vitro transcribed sgRNA.27 
1.3.1. Viral delivery of CRISPR/Cas9. Both lentiviral as well as adenoviral vectors have 
been widely used for CRISPR/Cas9 gene delivery.28 Lentiviral vectors provide a non-
specific high efficient integration of delivered gene into host genome and therefore is 
suitable for in vitro research. Adeno-associated viruses (AAV) provide controlled 
integration of delivered CRISPR genes into AAVS1 locus in mammalian cell systems, both 
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in dividing and non-dividing cells, and therefore this method is more appropriate for in 
vivo delivery that avoids toxicity arising from random integration. 29-32 Additionally, AAV 
is the most widely used among the viral vectors due to its non-immunogenicity and its 
specificity towards a vast range of serotypes.33 Recently, many studies have used this 
vector to deliver CRISPR elements into mice to correct mutated dystrophin gene in 
Duchenne muscular dystrophy (Dmd) disease.34,35 However, one major drawback of AAV 
vector is that this vector can package genes only up to the size of ~4.7 kbp.43 Therefore, 
Cas9 gene and sgRNA were delivered separately using two different AAV-vectors in these 
studies, as the size of Cas9 gene itself is 4.3 kbp. To overcome the problem of packaging 
limit, smaller CRISPR/Cas systems were discovered (SaCas9) that allowed the packaging 
both the SaCas9 gene and the sgRNA into a single AAV vector.36 
1.3.2. Non-viral delivery of CRISPR/Cas9. Non-viral synthetic delivery strategies are 
used for all formats of CRISPR delivery. Cas9 protein alongside sgRNA delivery (Cas9-
ribonucleoprotein or Cas9-RNP) is the most attractive format for non-viral delivery due to 
the low-risk associated with this format.27 In in vitro systems, various methods of 
delivering Cas9-RNP include—lipid nanoparticles,37 cell penetrating peptide based 
delivery,38 electroporation,39,40 and mechanical deformation41—which resulted efficient 
gene editing. The delivery efficiency for these methods, however, has not been reported.  
In in vivo systems, only a few Cas9-RNP delivery methods are reported so far. Lipid-
mediated (RNAiMAX) delivery of Cas9-RNP in mouse inner ear has demonstrated 
efficient genome modification at the injection site.37 Other studies of in vivo Cas9-RNP 
delivery include the use of DNA nanoclews (yarn-like DNA nanoparticles) and engineered 
Cas9 protein with multiple cell penetrating peptides.42 
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1.4. Challenges in CRISPR/Cas9 delivery 
While a few delivery systems have achieved some level of therapeutic gene editing, 
efficient editing remains a challenge. Different challenges associated with efficient 
therapeutic gene editing are discussed below. 
1.4.1. Packaging challenges. Packaging of CRISPR components into a single vector is a 
major challenge for therapeutic applications. As stated above, multiple components of 
CRISPR system are required to utilize the system. The packaging challenge is present in 
all the formats of delivery strategy i.e. gene, RNA, or protein-based delivery. For gene-
based delivery through AAV, the size limit of a cargo gene is ~4.7-kilo base pair (kbp).43-
45 However, the size of SpCas9 gene alone is ~4.3 kbp. Thus, inserting additional CRISPR 
components such as sgRNA, spare oligonucleotide or extra genes is challenging for single 
AAV vector-based CRISPR gene delivery.45 To overcome this problem, splitting Cas9 into 
two AAV vectors,46 or a smaller sized Cas9 has been demonstrated (SaCas9),47 however, 
their versatility for genome engineering applications remains to be investigated.  
Although most attractive, protein-based CRISPR delivery poses other challenges: 
while SpCas9 protein is a large protein (160 kDa, ~7.5 nm hydrodynamic diameter) with a 
net positive surface charge, sgRNA (~31 kDa, 5.5 nm hydrodynamic diameter) is 
negatively charged (~100 PO3
- groups).48 Thus, packaging these elements through 
supramolecular chemistry may be a major limitation for designing delivery vehicles. 
Moreover, incorporation of additional spare DNA (of size in kbp) for multiple applications 
may further complicate the vector design.  
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1.4.2. Targeted delivery. Viral vectors can be used for targeted CRISPR/Cas9 delivery, 
as these vectors provide tissue tropism.49 However, non-viral delivery of CRISPR 
components will require targeting moieties such as peptides or antibodies.50 This targeting 
is particularly difficult to achieve, as incorporation of additional biomolecules to a delivery 
vector alongside the CRISPR components complicates the packaging. 
1.4.3. Delivery and editing efficiency. CRISPR/Cas9 editing efficiency is determined by 
the delivery efficiency of the system. Low editing efficiency may be enough for alleviating 
certain diseases (e.g. muscular dystrophy, liver tyrosinemia), however, other diseases such 
as cancer may require as high as 100% editing efficiency. Unfortunately, in majority of the 
recently published CRISPR/Cas9 delivery research papers they did not mention the 
delivery efficiency.  
1.4.4. Off-target effect. One of the major limitations of CRISPR-based genome editing is 
its off-target effect.51,52 Even though the sgRNA is designed to target a specific gene of 
interest, often a significant number of non-specific genes are targeted by the same 
Cas9/sgRNA.  In gene-based CRISPR delivery, the long-term constitutive expression of 
Cas9/sgRNA further makes the problem worse: repeated exposure of Cas9/sgRNA to non-
specific genes can lead to large off-target effects. Different methods have been designed to 
reduce off-target effect including engineering high specificity Cas9 protein.53,54 Protein-
based CRISPR delivery, on the other hand, offers transient exposure of the host genome to 
the Cas9/sgRNA, that may result in reduced off-targeting events.38 
1.4.5. Immunogenicity. Since Cas9 or other CRISPR-based genome editing proteins are 
derived from bacteria, these systems are expected to elicit host immune response. 
Specially, gene-based delivery of CRISPR elements can permanently integrate Cas9 gene 
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into host cells. The constitutive expression of foreign Cas9 protein in the host cell will 
engage the MHC class I immune response which may result in the elimination of Cas9 
expressing cells in the host.55 Indeed, a recent study showed that AAV-based CRISPR 
delivery in vivo elicits a strong immune response against Cas9 protein but not against the 
vector itself.46 On the other hand, protein based CRISPR delivery system may offer 
minimal potential immunogenicity as delivered Cas9 protein will transiently present in the 
host cell (Table 1.1).  
1.4.6. Insertional mutagenesis. Many viral vectors are incorporated into random locations 
in the genome causing mutagenesis of essential genes. Gene therapy trials with retroviruses 
to treat SCID (Severe combined immunodeficiency) led to leukemic transformation after 
integration of the virus into the host genome.56 Insertional mutagenesis due to the 
integration of genes near a protooncogene may lead to tumorigenesis, illustrating the 
danger of gene-based CRISPR therapy. Protein/RNA delivery based CRISPR therapy, on 
the other hand, avoids this problem and thus is an attractive alternative to gene therapy 
(Table 1.1). 
 
1.5. Self-assembled nanostructures for intracellular protein delivery 
1.5.1. Self-assemblies. In biological systems proteins and other biomolecules are often 
trafficked in ‘tiny’ nanocontainers called vesicles.57 Both intracellular and extracellular 
protein transport is carried out through these exquisitely designed delivery vehicles.58 
Likewise, viruses carry their nucleic acids inside a container composed of capsid proteins.59 
These natural delivery systems are the result of molecular self-assembly of proteins and 
other biomolecular building blocks.60 Inspired by these naturally existing systems, a variety 
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of hierarchical self-assembled structures have been fabricated in recent years. Most of these 
materials were based on DNA,61,62 polymers,63 and inorganic nanoparticle building 
blocks64. Designing similar self-assembled hierarchical structures for any protein of 
interest with hybrid nanomaterials is challenging; as such an effort will require 
manipulating physiochemical properties of proteins (such as charges). Nonetheless, such 
structures with a desired protein may provide novel emergent functions including in 
intracellular protein delivery, enzymatic catalysis and photosynthetic energy harvesting.  
1.5.2. Gold nanoparticles. Gold nanoparticles (AuNPs) provide attractive building blocks 
for fabricating self-assembled functional structures. Monolayer protected AuNPs have 
particularly been employed in material science through the control of their surface 
functionality.65 The structure of AuNPs can be divided into two parts: a gold core, and a 
monolayer of organic ligands covering the core (Figure 1.3).66 This monolayer feature a 
hydrophobic chain to confer stability, a non-interacting oligo (ethylene glycol) moiety, and 
the surface interacting head-groups (Figure 1.3). The size of both the core and the surface 
monolayer can precisely be controlled, often to commensurate biological large molecules 
such as proteins and DNA.67 In addition, AuNPs exhibit a number of unique physical and 
chemical properties including their enormous surface area, oriented functionalities, and a 
functionalized surface with desired molecules. Such properties of AuNPs make them 
attractive building blocks for material fabrications, optical devices, chemical and biological 
sensor platforms, cellular imaging, and as drug delivery vehicles.68  
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Figure 1. 3. Structure of gold nanoparticles (AuNPs) used in this thesis work. AuNPs feature a 2-
nm gold core (yellow), and a surface organic monolayer comprising a hydrophobic chain, oligo 
(ethylene glycol) moiety, and a surface interacting head-group. 
 
1.5.3. Self-assembled protein-nanoparticle structures. AuNPs and proteins serve as 
attractive complementary building blocks for fabricating complex structures, allowing the 
incorporation of bio-functionality into the structures. Recently, various kinds of protein-
nanoparticle assemblies were constructed including protein–nanoparticle discrete 
assemblies,69 superstructures,70 and corona-like co-assemblies.71 These co-assemblies were 
either built based on self-templating proteins such as the viral capsid proteins,72 or relied 
on naturally existing complementary supramolecular interactions. Thus, these systems are 
restricted to a relatively narrow range of proteins; incorporation of any protein into a 
desired structure may require further engineering of the protein.  
1.5.4. Protein-nanoparticle co-engineering for fabricating self-assemblies. AuNPs can 
be easily engineered by functionalizing with a desired surface ligand. The surface ligand 
dictates the function of nanoparticles. A wide variety of chemical entities such 
hydrophobic, electrostatic,  interacting, and polar head groups can be placed on the 
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surface of a AuNP.73 As counterparts of these functionalized nanoparticles, proteins can be 
engineered with appropriate modifications. Both site-directed-mutagenesis to create 
specific mutations, as well as attaching a peptide sequence to one end of a protein provide 
means of engineering proteins. Once the proteins and nanoparticles are co-engineered with 
appropriate complementarity, we hypothesize that a wide variety of self-assembled 
nanostructures can be fabricated with emergent functions including for intracellular protein 
delivery.   
 
1.6. Dissertation overview 
The main goal of this thesis is to engineer biomimetic self-assemblies for 
intracellular delivery of proteins and CRISPR/Cas9 elements for therapeutic purpose. 
Molecular details of materials in nanoscale dictate their function in cell biology at 
macroscopic scale. Therefore, the rational design of the self-assemblies and their function 
as delivery vehicle for cell biology is thoroughly studied in this thesis. First two chapters 
(Chapter 2&3) will describe designing principle of self-assembled protein-nanoparticle 
materials, and rational co-engineering proteins and nanoparticles based on such principles 
to build higher order complex self-assemblies (Figure 1.4). In the last two chapters 
(Chapter 4&5), these nanoassemblies will be used to investigate their interactions with cell 
membrane, and delivery of protein and CRISPR/Cas9-RNP cargo into cells (Figure 1.4). 
Interfacing proteins and nanoparticles to build self-assemblies require finding 
recognition elements that can bring these two materials together. In chapter 2, we reported 
the creation of a reversible multivalent supramolecular "zipper" recognition motif between 
gold nanoparticles and proteins. In this assembly, carboxylate-functionalized nanoparticles 
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interact strongly with oligohistidine tags. This interaction was tuned through His-tag 
length, and offered unique binding profiles based on the pH and electrolyte concentration 
of the medium. 
Hierarchical organization of macromolecules through self-assembly is a prominent 
feature in biological systems. Synthetic fabrication of such structures provides materials 
with emergent functions such as intracellular protein delivery. In chapter 3, we reported 
the fabrication of self-assembled superstructures through co-engineering of recombinant 
proteins and nanoparticles. These structures featured a highly-sophisticated level of multi-
layered hierarchical organization of the components: individual proteins and nanoparticles 
co-assembled to form discrete assemblies that collapsed to form granules, which then 
further self-organized to generate superstructures of hundreds of nanometer size. The 
components within these superstructures are dynamic and spatially reorganize in response 
to environmental influences. The precise control over the molecular organization of 
building blocks imparted by this protein-nanoparticle co-engineering strategy provided 
strategy for creating hierarchical hybrid materials and formed the foundation for the cell 
biological application the following chapters. 
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Figure 1. 4. Thesis overview. Chapter 2 and 3 includes engineering molecular recognition elements 
between proteins and gold nanoparticles (AuNPs) for fabricating (A) simple, and (B) complex self-
assemblies. Chapter 4 &5 will describe the use these assemblies for direct cytoplasmic delivery of 
therapeutic proteins and CRISPR/Cas9 systems for gene editing (C). 
 
The applicability of our nanoassemblies reported in chapter 3 was tested in chapter 
4. Access to the cytosol is crucial for many protein-based therapeutic strategies, making 
endosomal entrapment a key challenge. We used our nanoassemblies to deliver proteins 
directly into cell cytosol. These assemblies fused with cell membranes, releasing the E-tag 
proteins directly into the cytosol. Five different proteins with diverse charges, sizes, and 
functions were effectively delivered into cells, demonstrating the generality of our method. 
Significantly, the engineered proteins retained activity after cytosolic delivery as 
demonstrated through the delivery of active Cre recombinase and Granzyme A to kill 
cancer cells. 
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Genome editing through the delivery of CRISPR/Cas9 system provides tremendous 
opportunity in curing human genetic diseases. Delivery of CRISPR elements in protein 
format (Cas9-ribonulceoprotein or Cas9-RNP) reduces unwanted gene targeting and 
avoids integrational mutagenesis that can occur through gene delivery strategies. Direct 
and efficient delivery of Cas9-RNP into the cytosol followed by translocation to the 
nucleus remains a major challenge in realizing the potential of CRISPR/Cas9 in human 
medicine. In chapter 5, we reported a remarkably high efficient (~90%) direct 
cytoplasmic/nuclear delivery of Cas9 protein through the co-engineering of Cas9 protein 
and carrier nanoparticles. This construct provided effective (~30%) gene editing efficiency 
and opened up opportunities in studying genome dynamics.  
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CHAPTER 2 
ENVIRONMENTALLY RESPONSIVE HISTIDINE-CARBOXYLATE 
ZIPPER FORMATION BETWEEN PROTEINS AND 
NANOPARTICLES 
 
 
2.1. Introduction 
Tailoring molecular recognition between synthetic materials and biomolecules 
provides a versatile strategy for creating bioconjugate systems.1  A variety of 
supramolecular approaches have been devised to interface synthetic and biological systems 
for diverse applications.2 However, using these systems in physiological environments 
such as serum is challenging, where high concentrations of proteins and other biomolecules 
compete for interaction.  
 Co-engineering of biomolecules and synthetic materials provides a strategy for 
generating high affinity and reversible molecular interactions.3 Inspiration for this co-
design can be obtained from Nature: naturally occurring molecular zippers, including 
duplex DNA4 and leucine zippers5 exhibit robust multivalent reversible interactions in 
intracellular conditions. Microtubules polymerize and de-polymerize through the 
formation of specific molecular zippers.6 This multivalent motif7 has been used to create 
synthetic molecular duplexes8 through non-covalent interactions including electrostatic 
interactions,9 hydrogen bonding,10 π-π interactions,11 and van der Waals forces to generate 
zippers.12  
 Multivalency is a key structural prerequisite for zipper motifs. Nanomaterials offer 
molecular scaffolds that can be engineered to present multivalent recognition elements.13 
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Gold nanoparticles (AuNPs) provide a particularly versatile platform for biomolecular 
recognition,14 and have been interfaced with proteins for a wide variety of applications.15 
The AuNP surface can be readily engineered to feature recognition elements. Additionally, 
AuNPs can be generated with sizes commensurate to proteins, providing surface 
complementarity for recognition while maintaining effective biological function.16 
 The metal ion-mediated oligohistidine-nitrilotriacetate recognition motif has been 
widely employed to capture proteins using nanomaterials.17 We hypothesized that the 
oligohistidine cationic tail18 used in this strategy could be employed as a zipper component 
for interaction with nanomaterials. In this report, we demonstrate a reversible molecular 
zipper between His-tagged proteins and carboxylate functionalized AuNPs. This zipper 
exhibits high affinity binding in physiologically relevant environments, including serum 
conditions. The system is also environmentally responsive, with binding dictated by 
solution pH. This new recognition motif presents opportunities for engineering specific 
molecular interactions between synthetic and biomolecules. 
 
Figure 2. 1. (a) Zipper formation between AuNP-COOH and N-terminus oligohistidine-tagged 
GFPs through carboxylate-histidine interaction (b) The chemical structure of 2 nm gold core 
naoparticle AuNP-COOH. 
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2.2. Results  
The host nanoparticle was provided by AuNPs (2nm core diameter) functionalized 
with anionic ligands (AuNP-COOH) that can interact with proteins without denaturation.19 
We next explored the interaction of these inherently multivalent carboxylate particles with 
a family of His-tagged green fluorescent proteins (GFP)20 (Figure 2.1). We cloned and 
purified three eGFP21 variants carrying different length of N-terminal His-tags: one His 
(1xHis-GFP), six His (6xHis-GFP), and twelve His (12xHis-GFP) to determine the 
required number of interactions.These proteins were all anionic, with predicted pI values 
of 5.8, 6.1, and 6.5, respectively.   
 The binding efficiency of AuNP-COOH with the His-tagged GFPs was quantified 
through fluorescence titration,22  utilizing the quenching properties of the AuNP.23 At low 
ionic strength (5 mM phosphate buffer, PB) AuNP-COOH bound both 12xHis-GFP and 
6xHis-GFP with high affinity (Figure 2.2a). The binding constant (KS) values for 12xHis-
GFP (Ks= 2.95 ±0.6 x 10
7 M-1) was ~3-fold higher than that of 6xHis-GFP (Ks= 7.8 ±0.38 
x 106 M-1), indicating that multivalency is crucial for zipper formation. Interestingly, more 
GFPs bound to each nanoparticle for 12xHis-GFP (n= 11.6 ±0.8) than for 6xHis-GFP (n= 
4.7 ±1), potentially due to decreased secondary repulsion between the anionic GFPs.24 No 
significant binding was observed with 1xHis-GFP within the nanoparticles concentration 
that were chosen for the study, demonstrating that specific zipper formation was required 
for interaction.   
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Figure 2. 2. The interaction of AuNP-COOH with His-tagged GFP variants. Fluorescence 
(λex=475 nm, λem=510 nm) titrations between nanoparticles  and GFPs (100 nM) in (a) 5 mM 
phosphate buffer (PB), and (b) PBS buffer (150 mM NaCl in 5 mM PB) at pH 7.4. The complex 
association constant (KS) and the binding stoichiometry (n) were determined using previously 
reported method.22 
 
 The pragmatic use of non-covalent bioconjugates requires high affinity interactions 
at physiological ionic strength. In previous studies, electrostatic interactions between 
nanoparticles and proteins were fully disrupted at quite low salt concentrations, typically 
10-50 mM salt.25 In contrast, high binding affinities were observed between AuNP-COOH 
and both 12xHis-GFP (Ks= 1.3 ±0.16 x 10
7 M-1), and 6xHis-GFP (Ks= 1.4 ±0.2 x 10
6 M-1) 
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in PBS buffer (150 mM NaCl in 5 mM PB, pH 7.4) (Figure 2.2b). Notably, a larger n value 
was observed for 12xHis-GFP compared to 6xHis-GFP, similar to the trend observed at 
low (5 mM) electrolyte concentration. 
Reversible zipper formation at physiologically relevant conditions. One of the key 
advantages of supramolecular bioconjugates is their ability to respond to environmental 
changes. pH is an important biological parameter. For example, normal tissues have a pH 
of 7.4, while tumor tissues have lower pH (~6 to 7).26 Additionally, pH decreases through 
the endosomal/lysosomal pathways inside cells, reaching a pH of ~4.8.27  In our system, 
the histidine tag in GFPs offers a potentially pH-switchable recognition scaffold. To 
explore this possibility, we investigated the pH and ionic strength dependent reversibility 
of the carboxylate-histidine zipper formation. Both 12xHis-GFP and 6xHis-GFP interacted 
strongly with AuNP-COOH below pH ~7.5 at physiological salt concentration (PBS). 
Significantly, above pH ~7.5 the carboxylate-histidine zipper disassembled, releasing the 
GFP from the nanoparticles surface (Figure 2.3a and 2.3b). As expected, 1xHis-GFP did 
not interact with nanoparticles at any condition (Figure 2.3c). Taken together, these studies 
demonstrated the pH response of the zipper motif. 
Reversible zipper formation in serum conditions. In vivo applications including 
protein and gene delivery require specific and reversible interactions between synthetic 
carrier materials and the cargo molecules in serum.28 Serum presents a complex 
competitive chemical environment featuring a high (~1 mM) concentration of protein,29 
making it challenging to engineer effective recognition motifs. We parametrically 
investigated the serum concentration and pH dependent reversibility of the carboxylate-
histidine zipper. At pH <7.5 and at 10% serum (cell culture condition), 12xHis-GFP 
28 
 
exhibited a high affinity binding towards AuNP-COOH (Figure 2.4a). Significantly, in 
55% serum condition (in vivo condition) at pH 7.5 there was substantial binding between 
AuNP-COOH and 12xHis-GFP (Figure 2.4c). While the binding isotherm is complex, 
considerable binding was observed at high nanomolar concentrations. In contrast, 6xHis-
GFP did not bind with AuNP-COOH at any serum condition under investigation (Figure 
2.4b), indicating that a high degree of multivalency is crucial for carboxylate-histidine 
zipper formation in complex biological environments.  
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Figure 2. 3. Responsiveness of the carboxylate-histidine zipper towards pH and salt concentration. 
Fluorescence titrations between 400 nM of AuNP-COOH and 100 nM of (a) 12xHis-GFP, (b) 
6xHis-GFP, and (c) 1xHis-GFP were performed parametrically varied pH and salt (NaCl) 
concentrations in 5 mM PB. The intensity of GFP released from nanoparticles was normalized 
against the intensity of free GFP. 
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Figure 2. 4. Reversible carboxylate-histidine zipper formation between AuNP-COOH and (a) 
12xHis-GFP, and (b) 6xHis-GFP at serum conditions. 400 nM of AuNP-COOH was titrated against 
100 nM of His-tagged GFPs varying the serum percentage and pH at 150 mM salt (1xPBS) 
concentration. (c) Fluorescence titrations between AuNP-COOH and 12xHis-GFP (100 nM) at 
55% serum condition, pH 7.4. 
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2.3. Conclusions  
In summary, we have tailored a molecular zipper based on multivalent carboxylate-
histidine interactions through co-engineering of the AuNP surface and proteins. The 
carboxylate-histidine zipper exhibited high affinity interactions under physiologically 
relevant conditions that were pH responsive, making these systems attractive starting 
points for delivery and imaging applications. In a broader context, these studies 
demonstrate how co-engineering of biomolecules and nanoparticles can be used to generate 
bioconjugates with new and useful properties. 
 
2.4. Experimental section 
Cloning and over expression of green fluorescent proteins (GFPs). Genetic 
engineering manipulation and protein expression were done according to standard 
protocols. (a) To generate 1xHis-GFP, a constitutive expression vector (pUCCB-ntH6-
eGFP) was purchased from Addgene (plasmid id- 32557).30 For the sake of purification, a 
6xHis tag was placed on the N-terminus of 1xHis-GFP, upstream of a thrombin cleavage 
site. (b) 6xHis-GFP expression vector (pET21-d-GFP) was obtained from Novagen. (c) 
12xHis-GFP was generated by incorporating twelve histidines in the N-terminus of GFP. 
Briefly, using GFP as the template, PCR was performed with the following primers. 
Subsequently, the PCR product was digested (using BamHI and HindIII restriction 
enzymes) and inserted into pQE80 vector, downstream of nucleotides for six histidine tag 
to construct pQE80-12xHis-GFP expression vector. Successful cloning was confirmed by 
DNA sequencing.  
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Forward primer: 5’- ACGATGGATCCCACCATCACCAT -3’  
Reverse primer: 5’- GTGACAAGCTTTTACTTGTACAGCTC -3’ 
 To produce recombinant proteins, plasmids carrying 1xHis-GFP, 6xHis-GFP, or 
12xHis-GFP was transformed into Escherichia coli BL21(DE3) strain. A transformed 
colony was picked up to grow small cultures in 50 mL 2xYT media at 37 0C for overnight. 
The following day, 15 mL of grown culture was inoculated into one liter 2xYT media and 
allowed to grow at 37 0C until OD reaches 0.6. At this point, the protein expression was 
induced by adding isopropyl-b-D-thiogalactopyranoside (IPTG; 1 mM final concentration) 
at 25 0C. After 16 hours of induction, the cells were harvested and the pellets were lysed 
using a microfluidizer. His-tagged fluorescent proteins were purified from the lysed 
supernatant using HisPur cobalt columns. The integrity and the purity of native protein 
were determined by 12% SDS-PAGE gel.  
 1xHis-GFP was cleaved from its 6xHis tag using thrombin-agarose beads 
(Thrombin CleanCleave™ Kit, Sigma-Aldrich) as described in the instruction manual. 
After the cleavage, 1xHis-GFP was passed through a HisPur cobalt column to remove the 
cleaved 6xHis tag.  Further, the residual 6xHis was removed by a 10KD-MWCO 
(molecular weight cut off) filter. 
Synthesis and characterization of nanoparticles. Carboxylate functionalized gold 
nanoparticles (AuNP-COOH) were synthesized according to a previous report.31 Briefly, 
Brust-Schiffrin two-phase synthesis was used to synthesize pentanethiol-coated AuNPs 
with core diameter ~2 nm.32   The Murray place-exchange method was followed to obtain 
AuNP-COOH.33 The monolayer protected nanoparticles were re-dispersed in water. The 
excess ligand/pentanethiol were removed by dialysis using a 10,000 MWCO snake-skin 
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membrane. The final concentration was measured by UV spectroscopy at 502 nm. To 
assess their quality, the nanoparticles were characterized by Zeta potential (surface charge), 
Dynamic Light Scattering (DLS) (hydrodynamic radius), and Transmission Electron 
Microscopy (TEM) (core size) as shown in Figure 2.5. 
Fluorescence titration. Fluorescence titration experiments between nanoparticles 
and GFPs were carried out as described previously.34 Briefly, the change of fluorescence 
intensity of GFPs at 510 nm was measured with an excitation wavelength of 475 nm at 
various concentrations of nanoparticles from 0 to 400 nM on a Molecular Devices 
SpectraMax M3 microplate reader (at 25 0C). Quenching of fluorescence intensity arising 
from 100 nM GFP was observed with increasing nanoparticle concentration. Nonlinear 
least-squares curve fitting analysis was carried out to estimate the binding constant (KS) 
and association stoichiometry (n, [GFP]/[AuNP-COOH]) using a one site binding model.21  
 For the pH and salt dependent interactions (fluorescence titrations) between 
nanoparticles and GFPs, the concentration of GFP chosen was 100 nM for each study. The 
concentrations of AuNP-COOH used for the titrations were 400 nM. The fluorescence 
intensity for each study was normalized against the intensity of GFP without nanoparticles 
at their respective pH and salt (NaCl in 5 mM PB) concentration. The titrations were carried 
out in triplicates, and repeated at least twice with different batches of nanoparticles.  
 Similar fluorescence titrations were performed for the serum concentration and pH 
dependent interactions between AuNP-COOH and His-tagged GFPs. Both the nanoparticle 
(400 nM) and GFP (100 nM) concentrations were kept fixed, varying the serum percentage 
and pH of the solutions. In a typical experiment, AuNP-COOH/GFP complexes were made 
first, incubated at dark for 10 minutes, then the required serum amount was added to the 
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complexes, followed by immediate shaking for 30 seconds. Fluorescence reading was 
taken after 30 minutes of incubation. 
 
2.5. Supporting figures 
 
 
 
Figure 2. 5. Characterization of AuNP-COOH. (a) Zeta potential (-34.8±3.1 mV, measured at 5 
mM PB, pH 7.4), (b) Dynamic light scattering (DLS) diameter (14.1±1.2 nm, measured at 5 mM 
PB, pH 7.4), and (c) TEM image of AuNP-COOH. 
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CHAPTER 3 
PROGRAMMED SELF-ASSEMBLY OF HIERARCHICAL 
NANOSTRUCTURES THROUGH PROTEIN-NANOPARTICLE CO-
ENGINEERING 
 
 
3.1. Introduction 
Complex self-assembled structures observed in Nature are formed through multiple 
levels of hierarchical organization.1 The components in these systems are spatially 
organized to acquire functions,2,3 evolving through dynamic reorganization during cellular 
processes.4 Building synthetic structures to mimic these complex dynamic assemblies is 
challenging.5,6 Recent studies have fabricated ordered discrete structures based on self-
assembly of DNA,7 proteins,8,9 and proteins with DNA.10 These structures mirror the 
structural complexity of biological systems, however their architectures are ‘fixed’ in 
lattice arrays, and lack the dynamic behavior of bioassemblies. Synthetic systems including 
nanoparticles11-13 and polymers5,14,15 have likewise been used to build hierarchical 
assemblies, however fabrication of dynamically-organized self-assembled hierarchical 
structures remains elusive.  
Nanoparticles and proteins serve as attractive complementary building blocks for 
fabricating ‘bricks and mortar’ hierarchical structures, allowing the incorporation of bio-
functionality into nanostructures. These nanoassemblies include discrete lattices,16 
superstructures,17 and corona-like co-assemblies.18 These co-assemblies were either built 
based on self-templating proteins such as viral capsid proteins,19 or relied on naturally 
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existing complementary supramolecular interactions between nanomaterials and wild-type 
proteins, restricting these systems to a relatively narrow range of proteins.  
We report here a protein-nanoparticle co-engineering approach that provides 
programmed self-assembly of dynamic superstructures. These assemblies exhibit multiple 
layers of structural hierarchy, with an organizational complexity similar to that of 
membrane-free intracellular assemblies (Figure 3.1). Our initial co-engineered system uses 
a green fluorescent protein (GFP) bearing a genetically incorporated glutamic acid peptide 
chain (E-tags). This engineered protein self-assembles with 2 nm core gold nanoparticles 
carrying arginine-terminated ligands (ArgNP)20 through carboxylate–guanidinium 
interactions21 to generate hierarchical nanostructures guided by electrostatic self-assembly. 
This assembly process is quite general, as demonstrated through the use of multiple 
proteins (Figure 3.1e-g). 
 
Figure 3. 1. Hierarchical organization of engineered proteins and nanoparticles into complex 
superstructures. (a) Chemical structure of the arginine functionalized gold nanoparticles ArgNPs, 
and b, schematic representation of different layers of protein–nanoparticle hierarchical 
organizations observed in a superstructure. (c) high, and (d) low magnification transmission 
electron microscopy (TEM) images of the superstructures. Inset in c is TEM image of a single 
granule in a superstructure, where black and white patches represent ArgNPs and GFP-E10 
respectively; red lines represent interparticle center-to-center distance. (e-g) Hierarchical 
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organization of different proteins with ArgNPs: Histone 2A-E10 (e), Cre recombinase E10 (f), and 
single chain antibody fragment scFv(ErbB2)-E10 (g). h, A tilt-section of a tomogram; and i, the 3D 
visualization of a reconstructed superstructure of GFP-E10:ArgNPs in (h), showing the surface 
(green) and the inner granules (blue). 
 
 
3.2. Results 
Fabrication of hierarchically organized protein-nanoparticle superstructures. In 
natural systems, controlled multivalency plays an important role in driving self-assembly 
and in the organization of molecules into higher ordered structures.22 We provided 
analogous control over our self-assembly process by engineering GFP with a series of 
different lengths of E-tags (GFP-En, where n= 0 to 20) at the C-terminus of the protein, a 
technique we previously to facilitate local interaction between engineered proteins and 
nanoparticles.38 We initially performed fluorescence titration experiments between GFP-
En and ArgNPs at physiologically relevant pH values (PBS, pH 7.4) to find the appropriate 
GFP variants for effective and dynamic interactions with ArgNPs. As expected, due to its 
negative overall charge, GFP-E0 exhibits weak binding with ArgNPs, while binding 
increased as the length of E-tag was increased to E10 (Figure 3.6). GFP-E15 and GFP-E20 
were bound poorly to the nanoparticles as compared to GFP-E10, presumably due to non-
specific aggregate formation with the higher length of E-tags. We therefor chose GFP-E10 
for studying the subsequent assembly formation (Figure 3.6).  
Self-organized superstructures were generated by mixing GFP-E10 and ArgNPs at 
3:1 (750:250 nM) molar ratio in PBS or in cell culture media (DMEM), and assembling at 
room temperature for 10 min, followed by a 30-min incubation at 37 °C. The resulting 
structures were inspected by electron microscopy and small angle X-ray scattering (SAXS) 
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experiments. Individual nanoparticles (2-nm core diameter) and proteins (ca. 3 nm) co-
assembled into large superstructures of ca. 250–350 nm diameter (Figure 3.1c and d). 
Transmission electron microscopy (TEM) studies at low magnification (Figure 3.1d) 
showed the formation of uniform superstructures, with higher magnification (Figure 3.1c) 
revealing magnified structures. Within the superstructures, three distinct layers of 
hierarchical organization of proteins and nanoparticles were observed. The first layer of 
hierarchical organization consisted particles surrounded by multiple proteins to produce 
‘corona-like’ structures (Figure 3.1b) of ca. 10 nm in overall diameter (Figure 3.1c, inset). 
These corona-like structures further evolved to produce ‘granule-like’ structures (<40 nm 
diameter) that comprise the second layer of hierarchical organization (Figure 1c, inset). 
The average center-to-center particle distance in these granular superstructures is ~10 nm, 
according to both TEM (Figure 3.1c inset) and SAXS measurements (Figure 3.8). These 
granular structures then assembled together to produce the final ~250–350 nm diameter 
superstructures (Figure 3.1b—i). This assembly process is generalizable: E10 tagged 
proteins featuring different sizes and pI values of the native protein (Histone 2A, pI=10.9, 
MW=14.1 kDa; Cre recombinase, pI=9.6, MW=38.5 kDa; single chain antibody fragment 
scFv, pI=8.4, MW=32.3 kDa) all generated hierarchical structures essentially identical to 
those observed with GFP-E10 (pI=5.9, MW=27 kDa) (Figure 3.1e-g). 
Detailed insight into the organized superstructures was obtained using EM 
tomography. Images of the 3D superstructures were obtained with capture angles from 
+600 to -600. Figure 3.10 shows a 3D density map, showing the surface structure of the 
superstructure. The 3D visualization provided by the reconstructed tomograms showed the 
packed inner granules (Figure 3.1h—i).  
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Environmental ionic strength dependent superstructure evolution. We next 
investigated the mechanism of superstructure formation. Many environmental factors 
trigger self-organization/re-organization of building blocks in cellular compartments, 
including pH (e.g., actin polymerization)23 and ion gradient (e.g., endosomes, neuronal 
signaling).24 Our system is electrostatic in nature, and is strongly dependent on the 
concentration of electrolytes in the solution. At low salt concentration (Figure 3.2a, 5 and 
10 mM) GFP-E10 and ArgNPs co-assembled to form extended ‘precursor’ clusters, 
however no superstructure formation was observed. With the increase in salt concentration, 
these granular precursors continued to evolve and the formation of larger superstructures 
started appearing at a salt concentration of 20 mM. Complete superstructure formation was 
observed at 50 mM salt, with no observable free GFP-E10:ArgNPs precursor clusters. The 
dynamics of the evolution of the assembly can be related to other recently reported 
assembly formation processes,25,26 in which ‘precursor’ clusters, but not individual proteins 
and particles, serve as the intermediate for the superstructure formation (Figure 3.7). While 
the morphology of the superstructures remained the same above 50 mM salt solutions, the 
size increased with increasing salt concentration of the solution (Figure 3.2a). An 
electrolyte-dependent-assembly evolution process was also supported by SAXS 
measurements (Figure 3.2b; Figure 3.8). With increasing ionic strength, a gradual increase 
in the peak intensity at 1/q ca. 0.06 Å was observed, corresponding to the interparticle 
center-to-center distance (dNP-NP), which resulted from assembly formation. The peak 
intensity reached saturation at 50 mM salt concentration, indicating complete 
superstructure formation, consistent with that observed by TEM measurements.  
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The electrolyte dependence of GFP-E10:ArgNPs superstructure formation can be 
qualitatively rationalized by electrical double layer formation around GFP-E10:ArgNPs 
clusters (Figure 3.7 red boxes).16,27,28 The magnitude of the electrical double layer is 
dependent on Debye screening length (𝛋-1), where 𝛋-1 is inversely related to the ionic 
strength of the solution (Experimental section). When ionic strength increases, 𝛋-1 
decreases; reducing the electrical double layer repulsion between GFP-E10:ArgNPs 
precursor clusters. At specific concentrations of salt, the double-layer repulsion becomes 
minimal, forcing the clusters to collapse to form a superstructure (Figure 3.2d; 
Discussions). The superstructure formation is further dictated by GFP-E10, as the 
polyvalency of the counterion is critical for the initial cluster formation (Figure 3.5d)29 
(Discussions); this behavior demonstrates the importance of co-engineering of 
nanoparticles and proteins for building these hierarchical superstructures. 
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Figure 3. 2. Superstructure evolution triggered by environmental ionic strength. (a) TEM images 
of salt-induced superstructures between GFP-E10 and ArgNPs. Scale bar: 100 nm. (b) SAXS 
inspection of superstructure formation at various salt concentrations showing the gradual intensity 
enhancement and a shift in q value arising from superstructure formation. (c) Comparison of inter-
particle distance (dNP-NP) of the assemblies with theoretical Debye length (𝛋-1) at different salt 
concentrations. (d) Physical principle governing superstructure formation. Yellow and green at the 
core are ArgNPs-proteins ‘clusters’ and the gray shell represents the Debye screening layer 
respectively. 
 
SAXS experiments further provided evidence for the electrolyte dependence of 
GFP-E10:ArgNPs superstructure formation, as the reduction in 𝛋-1 of ArgNPs correlated 
with increasing electrolyte concentration. As shown in Figure 3.2b (inset), with increasing 
ionic strength, the peak corresponding to dNP-NP shifted towards a higher q value, which is 
indicative of the reduction in 𝛋-1 values of ArgNPs. It is noteworthy that higher q value 
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signifies a decrease in the dNP-NP distance that is anticipated with the reduction of Debye 
screening length of the ArgNPs. We measured the dNP-NP from these SAXS peaks and 
compared with the theoretical 𝛋-1 values as a function of salt concentration (Figure 3.2c; 
Figure 3.8). As ionic strength increased, dNP-NP dropped until it reached a saturation point 
at 50 mM salt concentration. On the contrary, theoretical 𝛋-1 values continued to decrease 
beyond 50 mM salts; this discrepancy is presumably due to the steric "locking in" of the 
ArgNPs upon completion of superstructure formation (at 50 mM salt concentration). In the 
resulting assembly, there is no further room for the particles to come closer, a factor not 
accounted for in theoretical calculations of 𝛋-1. A slight increase in dNP-NP was observed 
beyond 50 mM salt concentration, which presumably arises from the molecular re-
organization of the building blocks within the superstructure (Figure 3.3). Taken together, 
these experiments indicate that complementarity and multivalency between building 
blocks are essential, but not sufficient for the evolution of higher ordered complex 
assemblies, and that environmental triggers play a decisive role for such processes.  
Dynamic and spatial organization of the superstructure components. Electrolytes 
govern the dynamic and spatial reorganization of the building blocks in these 
superstructures. As ionic strength was raised beyond 40 mM salt, the components within 
the superstructures undergo organizational transformation. At 40 mM salt, GFP-E10 and 
ArgNPs assembled into corona-like structures within the superstructure; these structures 
represent lower level molecular organization (Figure 3.3a, 40 mM). The size of an 
individual corona structure is ca. 11 nm in diameter (Figure 3.3b, 40 mM, marked by a red 
arrow, and in the inset), which suggests a corona composition of one particle at the core 
surrounded by ~3 proteins. As the salt concentration increased to 75 or 100 mM, multiple 
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GFP-E10:ArgNPs coronas coalesced to form bigger granular structures of ~20 nm in 
diameter. When salt concentration was increased to 150 mM, further condensation of GFP-
E10:ArgNPs was observed, with the size of these granules increasing to ~40 nm in diameter 
(Figure 3.3b—c at 150 mM).  
 
Figure 3. 3. Dynamic reorganization of the superstructure components. (a) High magnification 
TEM images of superstructures at different salt concentrations Scale bar: 50 nm. (b) A portion of 
each image from (a) was magnified. Scale bar: 20 nm. Individual nanoparticles (black) were 
surrounded by about three proteins (white) to form corona or granules as shown by red arrows. 
Inset showing enlarged corona (40 mM) or granules (75, 100, and 150 mM). (c) Schematics 
showing the molecular reorganization of the superstructure components as salt concentration 
increased. Yellow and green represent ArgNPs and GFP-E10, respectively.  
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3.3. Conclusions  
In summary, we have demonstrated that co-engineering of proteins and 
nanoparticles can be used to generate complex hierarchical assemblies with sophisticated 
structural and dynamic properties. The dynamic arrangement of the components within the 
superstructures is highly responsive to environmental stimuli. The ability to fabricate 
complex structures in this fashion presents systems for studying emergent behavior, as well 
as pursuing pragmatic applications including therapeutic delivery,30 catalysis, and 
photosynthetic energy harvesting.31 
 
3.4. Discussions 
Electrolyte dependent higher order superstructure formation. The stability of 
colloidal micro particles (P) in solution can be explained through classical Derjaguin-
Landau-Verwey-Overbeek (DLVO) theory.32 DLVO theory, in its simplest form, takes 
account for the electrostatic repulsion and van der Waal’s interactions between particles in 
solution. Briefly, the overall potential of Ps in solution is given by sum of repulsive and 
attractive forces: 
Vr= Vel + VvdW 
Where Vr is the overall potential at a ‘r’ center-to-center distance, Vel is the electrostatic 
repulsion, and VvdW is the van der Waals (vdW) attraction between the particles. Vel is 
determined by the Debye electrical double layer around the particles. At low salt 
concentration, when the Debye screening length is reasonably high, the repulsive and the 
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attractive forces counterstabilize the particles in solutions. However, when the salt 
concentration increases, the Debye electrical double layer shrinks and the attractive vdW 
forces dominate over the electrical double layer repulsion, causing the particles to 
aggregate in solution.  As mentioned, this is the simplest explanation of microparticle 
stability in solution by DLVO theory. In practice, however, due to complex nature of forces 
arising from interacting particles, modified DLVO theories are generated (extended-DLVO 
theory).33  
 Although the forces between nanoparticles (NPs) in solution remain same with Ps, 
classical DLVO theory fails to explain NP colloidal stability.28 The repulsive and the 
attractive forces of DLVO theory (VE and VvdW) may not be simply ‘added’ to predict the 
stability of NPs in solution: Kotov and his coworkers described this property as 
‘Nonadditivity of nanoparticle interactions’.28 There are numerous assumptions why 
nonadditivity of NPs interactions exist. For example, when the size of the particles is only 
a few nanometers, the size of the counterions (solvated ions) in the electrical double layer 
cannnot be considered as point particles which is in the case of DLVO theory. Other 
reasons of nonadditivity include: a) inorganic NPs are often functionalized with organic 
ligands to provide an interfacial layer that protect the core NPs. Thus, the inorganic core 
of the NPs and the surrounding interfacial organic layer cannot be assumed as uniform 
continua. b) NPs are often made from metals and semiconductors that have high 
polarizability. Collectively—dimensionality, topology, and polarizability—all contribute 
towards nonadditivity of NPs interactions. 
Several studies have shown that stability of NPs of size 50 nm or larger can be 
predicted by DLVO theory.34,35 Very recently, vdW interaction at ‘nanoscale’ between 
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complex nanostructures such as proteins and nanowire have been predicted.36 Thus, it is 
evident that the additive properties of various forces of DLVO theory may not accurately 
predict NP aggregation, nonetheless, these very forces play major roles in stability or 
aggregation of these particles. Therefore, the contribution of vdW forces is crucial for NPs 
assembly. In fact, by increasing the electrolyte concentration to minimize the electrical 
double layer of nanoparticles Kostiainen et. al. has managed to fabricate 2D crystal lattice 
like structures from these NPs.16 In another example, Grzybowski and his coworkers 
fabricated diamond-like lattice structures from oppositely charged binary nanoparticles by 
manipulating forces at nanoscale.27,37 
In the light of above theoretical and experimental background, a partial explanation 
for higher order nanoparticle aggregation by our system can be provided. As mentioned in 
the manuscript our ArgNPs have a core size of ~2 nm diameter and ~3-4 nm of interfacial 
ligands surrounding the core. The dimension and the lack of uniform continua make the 
ArgNPs deviate from DLVO prediction of colloidal stability. Indeed, when the salt 
concentration of ArgNP solution was increased to 150 mM to reduce the Debye screening 
length, the particles were still stable and did not aggregate (Figure 3.5b) in contrary to 
DLVO prediction for P. As E-tagged proteins are added to ArgNPs solution at low salt 
concentration, the binary protein-nanoparticles started forming small aggregates via simple 
electrostatic interactions that we called ‘precursor clusters’. The size of these clusters is 
~30-40 nm in diameter (Figure 3.5d; Figure 3.7; 5, 10, and 20 nm; red box). [Note that 
these clusters may be the basis of the granule structures (2nd level of assembly) that are 
observed at higher salt concentration. Also, the first layer of hierarchical assembly i.e. the 
corona-like structures are buried within these clusters and they may not exist as 
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independent entity in our study.] When the salt concentration is increased the electrical 
double layer around these clusters is expected to shrink, resulting in reduced electrostatic 
repulsion between the clusters. At this point, the dominating attractive forces (i.e. vdW and 
other undetermined attractive forces, though they do not obey additivity) may trigger the 
clusters to collapse together to form the superstructures (3rd layer of hierarchical assembly). 
We must point out here though is that the explanation we provided for higher order 
hierarchical assembly formation by our system is a simplistic version. In reality, further 
theoretical and computational assistance are required to fully understand the aggregation 
mechanism. 
Importance of the ligand on the surface of gold nanoparticles. A single gold 
nanoparticle (AuNP) accommodates hundreds of arginine-functionalized thiol ligands 
(HS-C11-TEG-NH-Arginine) on its surface (Figure 3.4). The resultant AuNPs acquires 
multivalency, prerequisite for a strong supramolecular interaction with E-tagged proteins. 
In contrast, if only a single ligand (Figure 3.4, compound 7) is used, the interaction with 
E-tagged proteins will not be strong enough for assembly formation.   
 Different components of the ligand are also crucial for the stability and function of 
the particles. As shown in Figure 3.4, the thiol (HS) group pins the ligand to the gold 
surface, the hydrophobic C11 group stabilizes the nanoparticle, the tetraethylene glycol 
(TEG) moiety confers biocompatibility on the particle, and the arginine head group dictates 
the interaction with E-tagged proteins though supramolecular arginine–carboxylate 
interactions.  
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Influence of counter ion on superstructure formation- Schulze-Hardy rule. 
Coagulation of colloidal particle is driven by the charge state of the oppositely charged 
counter ions.29  
Critical concentration of coagulation (Ccrit) is given by- 
Ccrit ∞ Constant/Z6 
where,  
Z is the valence state of the counter ion (GFP-E10, in our case). 
 
3.5. Experimental section 
 
Nanoparticle engineering. Arginine-functionalized gold nanoparticles (ArgNPs) 
were prepared according to our previous methods.20 Briefly, the arginine-functionalized 
thiol ligand was synthesized first (Figure 3.4a). Nanoparticles were subsequently prepared 
by conventional place-exchange reaction of 2-nm sized 1-pentanethiol-protected gold 
nanoparticles (Au-C5) with HS-C11-TEG-NH-Arginine (Compound 7) ligand (Figure 
3.4b). The resultant ArgNPs were dissolved in distilled water, purified by dialysis, and 
characterized (Figure 3.5).  
Engineering E-tagged proteins. Engineering of GFP-En (where n is the number of 
glutamic acids) and protein expression were done according to standard protocols. GFP 
gene was PCR-amplified and cloned into a bacterial expression vector (pQE80) with 6×His 
at the N-terminus. The following primers were used to amplify GFP gene: 
Forward primer: ACGATGGATCCATGGTGAGCAAGGG 
Reverse primers: 
GFP-E0: GTGTAAGCTTTTACTTGTACAGCTC 
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GFP-E3: GTGTAAGCTTTTATTCTTCCTCCTTGTACAGCTC 
GFP-E5: GTGTAAGCTTTTATTCCTCTTCTTCCTCCTTGTACAGCTC 
GFP-E7: GTGTAAGCTTTTACTCCTCTTCCTCTTCTTCCTCCTTGTACAGCTC 
GFP-E10: 
GTGTAAGCTTTTACTCTTCCTCCTCCTCTTCCTCTTCTTCCTCCTTGTACAGCT 
GFP-E15: (GFP-E5 as template)     
GTGTAAGCTTTTACTCTTCCTCTTCTTCCTCTTCCTCCTCTTCTTCCTCTTCTTC 
GFP-E20: (GFP-E15 as template) 
GTGTAAGCTTTTATTCCTCTTCTTCTTCCTCTTCCTCTTCTTCCTCTTC 
Amplified products were digested with restriction enzymes BamHI and HindIII, 
ligated into pQE80 vector, and transformed into bacteria. Positive clones were identified 
by using DNA sequencing. 
To produce recombinant proteins, plasmids carrying the GFP-En variants were 
transformed into E. coli BL21(DE3) strain. A transformed colony was picked to grow small 
cultures in 50 mL 2×YT (Yeast-Tryptone) media at 37 °C for overnight. The following 
day, 15 mL of grown culture was inoculated into one liter 2×YT media and allowed to 
grow at 37 °C until OD reached 0.6. At this point, the protein expression was induced by 
adding isopropyl-b-D-thiogalactopyranoside (IPTG; 1 mM final concentration) at 25 °C. 
After 16 hours of induction, the cells were harvested and the pellets were lysed by using 
1% Triton X-100 and subsequent DNAse-I treatment. Proteins were purified from the lysed 
supernatant by using HisPur cobalt columns. The integrity and the purity of native protein 
were determined by using 12% SDS-PAGE gel. Notably, the insertion of E-tag did not 
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affect the protein expression and purification, and the yield was equivalent to the 
expression of wild-type GFP. 
E10-tagged Histone 2A, Cre recombinase, and single chain antibody fragment scFv 
(scFv-anti-ErbB2) was similarly cloned and expressed in E. coli BL21 Rosetta strain.  
Fluorescence titration. Fluorescence titration experiments between nanoparticles 
and GFP-En were carried out as described previously.38 Briefly, the change of fluorescence 
intensity of GFP-En at 510 nm was measured with an excitation wavelength of 475 nm at 
various concentrations of nanoparticles from 0 to 400 nM on a Molecular Devices 
SpectraMax M3 microplate reader (at 25 °C). Quenching of fluorescence intensity arising 
from 100 nM GFP-En was observed with increasing nanoparticle concentration. Nonlinear 
least-squares curve fitting analysis was carried out to estimate the binding constant (KS) 
and association stoichiometry (n, [GFP-En]/[ArgNP]) by using a one-site binding model.39 
Superstructure fabrication. GFP-En:ArgNPs superstructures were prepared 
through a simple mixing procedure. ArgNPs (50 M stock in 5 mM PB, pH 7.4) were 
added to 100 L of 1×PBS, followed by adding GFP-En (50 M stock in 5 mM PB, pH 
7.4) at appropriate molar ratio [usually at 1:3 ratio (ArgNP, 250 nM)/(GFP-En, 750 nM) 
for most of the applications]. The complex was incubated at room temperature for 10 min. 
DMEM media (low glucose) or 1×PBS (or pure NaCl solution) was added to the complex 
to make the final volume up to 500 L. For the salt concentration-dependent assembly 
studies proteins and NPs were initially mixed in 5 mM PB, then the salt concentration was 
gradually adjusted by adding required salt solution. The superstructures were then 
incubated at 37 °C for 30 min for TEM, and SAXS studies.  
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Superstructures of other proteins were similarly fabricated using following molar 
ratios: H2A-E10:ArgNPs (3:1); Cre recombinase-E10:ArgNPs (1:2); and scFv-
E10:ArgNPs (1:2). 
Transmission electron microscopy (TEM). 10 L of the superstructure solution was 
drop-cast on to a TEM grid (carbon film- 400 mesh copper, electron microscopy sciences) 
and the sample allowed to dry at room temperature overnight. Superstructures were 
inspected by using JEOL 2000FX TEM. 
TEM Tomography, reconstruction of tomographic tilt series, and 3D modelling. 
TEM Tomography was performed using JEOL 2200FX TEM. Samples were prepared 
similarly as for regular TEM in grids (carbon film—150 mesh copper). Tilt series were 
acquired from -60o to +60o. Reconstructed tomograms were generated using IMOD/eTomo 
interface acquisition systems. For 3D visualization, reconstructed tomograms were further 
segmented and modelled using 3dmod. The 3D density maps of the corresponding 
tomograms were generated using UCSF Chimera.40  
Small angle X-ray scattering (SAXS). GFP-E10:ArgNPs superstructure samples for 
SAXS experiments were prepared as described above, with slight modifications. Briefly, 
ArgNPs (50 M stock in 5 mM PB, pH 7.4) were added to 20 L of PB such that the final 
concentration of nanoparticles became 2 M in 200 L volume. Then GFP-E10 (50 M 
stock in 5 mM PB, pH 7.4) was added into the nanoparticle solution (final protein 
concentration = 6 M). Superstructures were allowed to form at room temperature for 10 
min; then for 30 min after making up the volume to 200 L with appropriate buffer with 
necessary salt concentration. 75 L of each sample was drop-cast on a kapton film and 
allowed to dry at room temperature. Alternatively, solution samples were prepared by 
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placing 100–200 L of the superstructure solution into SAXS sample holder between two 
mica sheets. Samples were analyzed by using Ganesha SAXS-LAB (Northampton, 
Massachusetts).  
Calculation of Debye screening length (𝜅−1). 𝜅−1 was calculated using following 
equation.16 
𝜅−1 =  √
𝜀0𝜀𝑟𝑘𝑏𝑇
𝑒2∑𝑖𝑐𝑖𝑧𝑖
2 
where, 
 𝜅−1= Debye screening length 
𝜀0= Vacuum permittivity  
𝜀𝑟= Dielectric constant of solvent (water) 
𝑘𝑏= Boltzmann constant 
𝑇= Absolute temperature 
𝑒= Elementary charge 
𝑐𝑖= Concentration of electrolyte ions (NaCl) 
𝑧𝑖= Valencies of electrolyte ions 
 
 
3.6. Supporting figures 
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Figure 3. 4. Schemes for the synthesis of ArgNPs. a, the synthesis and the chemical structure of 
arginine ligand (Compound 7), and b, place exchange for preparing gold nanoparticles (ArgNPs). 
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Figure 3. 5. Characterization of ArgNPs and GFP-E10:ArgNP assemblies. a, TEM image of 
ArgNPs. b, DLS measurement indicating the hydrodynamic size of ArgNPs at various salt 
concentrations. The hydrodynamic size of nanoparticles decrease as the salt concentration increases 
due to the reduction of Debye electrical double layer. c, Electrokinetic potential (+20.8 mV) of 
ArgNPs. d, DLS size distribution of GFP-E10:ArgNPs assembly at various salt concentrations. The 
gradual formation of superstructures (<300 nm, diameter) from intermediate precursors (~30 nm, 
diameter) was observed as the salt concentration was increased (also see Figure 3.2). e, DLS size 
of GFP-E10:ArgNPs assembly at high salt concentration (300 mM) showing large aggregation.   
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Figure 3. 6. Titration of GFP-En with ArgNPs. Fluorescence titration between GFP-En (100 nM) 
and ArgNPs (0-400 nM) under physiologically relevant conditions (150 mM salt, pH 7.4). As the 
length of E-tag on GFP was increased the interaction with ArgNPs increased, reaching a maximum 
at E10 (GFP-E10). Surprisingly, investigation of binding affinity revealed that GFP-E15 and GFP-
E20 bound poorly to nanoparticles compared to GFP-E10, presumably due to the aggregation 
formation at higher length of E-tag. The binding constant (Ks=2.4±0.2 × 108 M-1) and binding ratio 
(n=2.9) between GFP-E10 and ArgNPs was determined by using an algorithm as described 
previously.39 
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Figure 3. 7. ‘Precursor’ based growth dynamics (evolution) of superstructures. a, At low salt 
concentration (5–10 mM), GFP-E10 and ArgNPs assembled to form cluster-like precursors (red 
box) for superstructure growth. However, as salt concentration increased beyond 10 mM, these 
precursor clusters condensed and continuously evolved (red arrow) to form larger superstructures. 
b, A model for superstructure evolution. These growth dynamics are similar to the growth of natural 
minerals such as silicate-1 that was recently reported by Lupulescu et al.25 
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Figure 3. 8. Small angle X-ray scattering (SAXS) investigation of superstructure formation. a, 
SAXS 2D-scattering data showing gradual GFP-E10:ArgNPs superstructure formation with 
increasing salt concentration indicated by a ring arising from the spacing of particles in the 
superstructure. b, 1D-scattering peak corresponding to the ring in (a). The peaks indicate the 
interparticle center-to-center distance (dNP-NP). c, Comparison of dNP-NP with Debye screening length 
(𝛋-1) at different salt concentrations. 
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Figure 3. 9. Superstructure formation by different E-tagged proteins, featuring similar structure 
and dynamic properties as of GFP-E10. An E10 tag was attached to proteins having different pI 
and molecular weight [Histone 2A (native pI=10.9, MW=14.1 kDa); Cre recombinase (native 
pI=9.6, MW=38.5 kDa); and a single chain antibody fragment scFv(ErbB2) (native pI=8.4, 
MW=32.3 kDa)]. Superstructures were fabricated similar to that of GFP-E10 and was investigated 
by TEM.  
 
Figure 3. 10. 3D visualization of the GFP-E10:ArgNPs superstructures. a, 3D density map showing 
the surface structure of the superstructure. b, Front view of a reconstructed superstructure, showing 
the surface (green) and the inner granules (blue). 
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CHAPTER 4 
A GENERAL STRATEGY FOR DIRECT CYTOPLASMIC PROTEIN 
DELIVERY VIA PROTEIN-NANOPARTICLE COENGINEERING 
 
4.1. Introduction 
Intracellular delivery of proteins into cells is crucial for therapeutic development,1 
cellular imaging and diagnosis,2 genome engineering,3,4 and synthetic biology 
applications.5 Native enzymes and transcription factors are particularly attractive 
‘biologics’ for intracellular enzyme replacement therapy,6,7 however effective delivery of 
these potential therapeutics remains elusive.7 Endosomal entrapment is a key hurdle: 
nanocarrier-based delivery methods result in only a fraction of the entrapped cargo (often 
~1%) escaping into the cytosol.8 Protease-mediated degradation and exocytosis of the 
remaining entrapped cargo make these strategies ultimately highly inefficient.8-10 Delivery 
through membrane disruption methods can provide efficient cytosolic protein delivery, 
however, these methods require additional osmolytic surfactants,11 hypertonic agents,12 or 
mechanical distortion techniques13 that are harmful for the cells and have challenges for in 
vivo enzyme applications.  
Recently, our laboratory has developed a nanocapsule-based14 strategy for cytosolic 
protein delivery.15-17 This method, however, is limited to proteins whose pI values are 
below ~7. More recently, we developed an engineering strategy to form spherical 
hierarchical self-assemblies between proteins and nanoparticles.18 In our approach, 
proteins tagged with recombinantly attached oligo-glutamic acid (E-tagged proteins) self-
assemble with positively charged gold nanoparticles (2 nm core diameter) that carry 
arginine functionality on their surface (ArgNP).14,19 We report here the use of these 
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assemblies as a general strategy for direct cytosolic delivery of proteins into mammalian 
cells, with versatility demonstrated using five different proteins with diverse charge, size, 
and function (Figure 4.1).  
 
Figure 4. 1. Co-engineering of E-tagged proteins and nanoparticles for direct cytoplasmic protein 
delivery. a) Strategy for protein engineering, and the chemical structure of arginine functionalized 
gold nanoparticles (ArgNPs). b) Simple mixing of E-tagged proteins and ArgNPs resulted 
hierarchical nanoassembly formation. c) Representative transmission electron micrograph (TEM) 
of GFP-E10:ArgNPs assemblies. Red arrow indicates access nanoparticle coating on the 
nanoassembly surface. d) Proposed fusion-like mechanism for direct cytosolic protein delivery. 
 
4.2. Results 
Engineering E-tagged green fluorescent proteins (GFP) for direct cytoplasmic 
delivery. For imaging purposes, we began our studies using GFP. We expressed a series of 
GFPs carrying different lengths of E-tags at the C-terminus and self-assembled them with 
Arg-NP particles.18 The assemblies were then screened for delivery efficiency in cultured 
HeLa cells. After incubating GFP-En:ArgNPs assemblies with HeLa cells for 3 h, the 
cellular uptake of GFP-En was monitored using confocal laser scanning microscopy 
(CLSM) and flow cytometry. GFP delivery efficiency increased as the length of E-tag 
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increased with maximum delivery at GFP-E10 (Figure 4.2e, Figure 4.8), consistent with 
our prior self-assembly studies.18 The highest GFP delivery intensity observed at a ratio of 
1: 3 ArgNP to GFP-E10 (750 nM), as determined by flow cytometry analysis (Figure 4.9). 
 
Figure 4. 2. Nanoassembly mediated cytoplasmic delivery of E-tagged GFP in Hela (a-d) and other 
cell lines (e). GFP-E10 is delivered into cytosol in HeLa cells (b), but not unmodified GFP (GFP-
E0) (a). c) Enlarged image of a GFP-E10 delivered cell, indicating thorough distribution of 
delivered protein in the cytoplasm and nucleus. d) Flow cytometry data showing GFP-En delivery 
efficiency increases as the E-tag length increases, reaching maximum at GFP-E10. Delivery 
efficiency dropped after E-tag length more than E10 due to inefficient assembly formation. e). GFP-
E10 delivery in different cell lines. 
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Confocal microscopy investigation revealed that the delivered GFP-E10 was 
evenly distributed throughout the cytoplasm (Figure 4.2b-c; Figure 4.10 for z-stacking 
images), without the punctate fluorescence seen with delivery vehicles with endosomal 
uptake (Figure 4.11).20,21  We also observed fluorescence in the nucleus, consistent with 
the ability of small proteins like GFP to diffuse across the nuclear pore (Figure 4.2b-c).22 
Direct cytoplasmic delivery of GFP-E10 is also evident from live cell video imaging. As 
shown in Figure 4.3b, the release of GFP-E10 was observed at ~15 min post-incubation, 
with complete protein delivery obtained in as little as 40 min. We choose five additional 
mammalian cell lines to demonstrate the generality of the delivery process: human 
embryonic kidney cells (HEK), mammary epithelial cells (MCF-7), mouse macrophage 
(RAW 264.7), human ovarian cancer cells (SKOV-3), and T-lymphocyte cells (Jurkat). As 
shown in Figure 4.2e and Figure 4.12, efficient cytosolic delivery of nanoassembly-
mediated GFP-E10 was evident in all of these cell lines, indicating the broad delivery 
capabilities of our system. 
A fusion-like process facilitates direct cytosolic protein delivery. Insight into the 
delivery process was obtained using time-lapse confocal microscopy. After contact of a 
nanoassembly with the cell membrane (Figure 4.3a), encapsulated GFP-E10 was quickly 
released into the cytosol (Figure 4.3c), reaching the opposite end of the cell in less than 30s 
and visible in the nucleus after 90s (Figure 4.3c). Significantly, free mCherry protein in the 
media did not enter the cell during nanoassembly mediated GFP-E10 delivery (Figure 
4.14), indicating that delivery does not occur through a “hole punching” process.23 
Mechanistic insight was obtained through cholesterol depletion assays, where complete 
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inhibition of protein delivery (Figure 4.13) was observed. This shut-down suggests that the 
delivery process occurs through a lipid raft mediated process.24  
 
Figure 4. 3. A fusion-like mechanism for nanoassembly-mediated direct cytosolic protein delivery. 
a) Confocal microscopy images showing nanoassemblies bound to the cell membrane (indicated 
by red arrow) in SKOV-3 cells that may eventually deliver the protein content to the cytosol. 
Inset—enlarged image of nanoassemblies. 3D image was reconstructed from z-stacking images. b) 
Time-lapse confocal microscopy imaging revealed the direct cytosolic delivery of GFP-E10 in 
HeLa cells. Representative still-images showing at 10, 20, and 30 min after nanoassemblies were 
added to the cell culture dish. c) A single nanoassembly (red arrow) was fused to the cell membrane 
(at -1s), which then rapidly released encapsulated GFP-E10 into the cytosol. Delivered GFP-E10 
was distributed thorough the cytosol (after 30s), and the nucleus (90s). 
 
A general strategy for direct cytosolic protein delivery. We selected five different 
proteins with a range of charge (pI), size, and function: Prothymosin- (pI= 3.71, MW= 
11.8 kDa, chromatin remodeling protein);25 GFP (pI= 5.9, MW= 27 kDa, imaging 
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protein);26 Granzyme A (GzmA) (pI= 9.14, MW= 29.0, cytolytic protein secreted by T-
cells);27 Cre recombinase (Cre) (pI= 9.60, MW= 38.5, DNA recombinase);28 Histone 2A 
(H2A) (pI= 10.60, MW= 13.5, DNA packaging protein in the nucleosome) (Figure 4.4a).29 
We attached an E10-tag to these proteins similar to GFP, at either the N- or C-
terminus (Experimental section). For imaging studies, these proteins (except GFP) were 
labeled with fluorescein isothiocyanate (FITC) and assembled with ArgNPs at the 
appropriate molar ratios (Experimental section). These nanoassemblies were incubated 
with HeLa cells at 37°C and 5% CO2 for 3 h. As shown in Figure 4.4b, all E10-tagged 
proteins were evenly distributed in the cytosol as well as the nucleus, establishing the 
generality of the protocol.  
 
Figure 4. 4. Direct cytoplasmic delivery of multiple E-tagged proteins with diverse size/charge, 
and functions. a) List of proteins delivered here with their respective charge (pI) and size (MW). 
b) Nanoassembly mediated delivery of these E-tagged proteins (FITC-labelled) indicated the even 
distribution in the cytoplasm and nucleus as shown through confocal microscopy images. Note that, 
except Cre recombinase, these proteins have inherent nuclear signal, which is also reflected by their 
preferential accumulation in the nucleus. 
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Functional delivery of Cre recombinase provides efficient gene recombination. Cre 
recombinase delivery provides an attractive tool for cellular engineering and synthetic 
biology applications. After achieving successful delivery of FITC-tagged Cre-E10, we 
tested its activity and function in the delivered cells. Cre excises out (delete) genes flanked 
by a recognition sequence ‘loxP’.30 To generate a simple readout of Cre activity, we 
generated a plasmid (loxP-dsRedSTOP-loxP-GFP) and delivered it into human embryonic 
kidney cells (HEK) for transient expression of the cassette. These cells exhibit red 
fluorescence, but will turn green after delivery of active Cre. When Cre-E10 was delivered 
into these reporter cells, red-to-green fluorescence conversion was observed using confocal 
microscopy and flow cytometry (Figure 4.5). Prominent expression of GFP was observed 
after 48 h of delivery, indicating that Cre-E10 was delivered in active form.  
 
Figure 4. 5. Nanoassembly mediated Cre-E10 delivery resulted efficient gene recombination. 
Confocal micrograph and flow cytometry data before (a), and after (b) Cre-E10 delivery in HEK 
cells. Delivery of Cre-E10 efficiently floxed dsRed gene, thus turning on GFP expression (b). 
 
Functional delivery of Granzyme A efficiently kills cancer cells. GzmA delivery 
provides a direct therapeutic application of intracellular protein delivery. Granzymes are 
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cytolytic enzymes that are produced by cytotoxic T-cells and released into target cells to 
kill them,31 a process used in adoptive cancer immunotherapy.32 The killing efficiency of 
delivered GzmA-E10 in HeLa cells was evaluated by incubating nanoassemblies 
containing GzmA-E10 were incubated with HeLa cells at 37°C and 5% CO2 for 3 h 
followed by washing. Cell death was assessed immediately or 24 h after, using confocal 
microscopy, phosphatidylserine staining, and caspase 3/7 staining. As shown in Figure 4.6, 
GzmA-E10 mediated cell death was observed 24 h after the delivery, but not after 3 h. 
Staining of phosphatidylserine, which is expressed on granzyme-mediated dead cells, 
confirmed that the slow cell death was indeed caused by delivered GzmA-E10 activity 
(Figure 4.6).33 On the other hand, GFP-E10 delivery did not cause cell death, indicating 
the specificity of delivered GzmA-E10 (Figure 4.6, bottom panel). Further, delivered 
GzmA-E10 killed the cells through a caspase 3/7 independent pathway (Figure 4.15), 
another hallmark of granzyme-A mediated cell death.34 Taken together, nanoassembly-
mediated GzmA-E10 delivery may provide an efficient means for intracellular protein 
therapy for cancer treatment.  
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Figure 4. 6. Nanoassembly-mediated delivery of functional Granzyme A-E10 (GzmA-E10) 
effectively killed HeLa cells. Confocal microscopy images showing FITC-GzmA-E10 or GFP-E10 
delivered cells along with phosphatidylserine staining. a) 3, and 24 h after GzmA-E10 delivery. b) 
24 h after GFP-E10 delivery. Note that 24 h after GzmA-E10 delivery cells died, which also showed 
phosphatidylserine staining, confirming the GzmA-E10 mediated cell death. 
 
4.3. Conclusions 
In summary, we present here a general method for direct cytoplasmic protein 
delivery through co-engineering of proteins (E-tagged) and functionalized nanoparticles. 
The versatility of our method was established by delivering five proteins with diverse sizes, 
charges, and functions. This system provides a useful tool for cell biology applications in 
vitro, and the potential for new intracellular enzyme replacement therapies for in vivo 
systems. Additionally, our technology may offer new ways for imaging intracellular 
protein trafficking and dynamics for understanding cellular protein function. Further, we 
75 
 
envision that out method can be applied for many desired proteins for applications 
including in synthetic biology and genome engineering. 
 
4.4. Experimental section 
Engineering E-tagged protein. A series of glutamic acid tags (E-tag) with different 
length was inserted to the C-terminus of GFP according to our previous method. Similarly, 
a E10 tag was inserted to Cre recombinase (N-term), Granzyme A (N-term), Histone 2A 
(C-term), through restriction cloning.  
 Recombinant proteins were expressed in E. coli BL21 Rosetta strain using standard 
protein expression protocol. Briefly, protein expression was carried out in 2xYT media 
with an induction condition of 1 mM IPTG and 18/25 oC for 16 hours. At this point, the 
cells were harvested and the pellets were lysed by using 1% Triton-X-100 (30 min, 37 oC) 
/DNase-I treatment (10 min). Proteins were purified using HisPur cobalt columns. Note 
that except GFP-En, proteins were eluted using high salt concentration buffer (2 M NaCl, 
300 mM Imidazole) due to the high positive charge of the proteins. Proteins were finally 
preserved in PBS buffer containing 300 mM salt, (Histone 2A, 750 mM salt). The purity 
of native proteins was determined using 12% SDS-PAGE gel. 
Nanoparticle synthesis and characterization. Arginine-functionalized gold 
nanoparticles (ArgNPs) were synthesized according to our previous protocol.14 Briefly, 
after synthesizing the arginine-functionalized thiol ligand, ArgNPs were prepared by 
conventional place-exchange reaction of 2-nm sized 1-pentanethiol-protected gold 
nanoparticles (Au-C5) with HS-C11-TEG-NH-Arginine. The resultant ArgNPs products 
76 
 
were dissolved in distilled water, and purified by dialysis in 5 mM phosphate buffer (PB) 
(Figure 4.7).  
Nanoassembly fabrication. Nanoassemblies of ArgNPs with various E-tagged 
proteins were fabricated through a simple mixing method, according to our previous 
method.18 ArgNPs (50 M stock in 5 mM PB, pH 7.4) were first added to 100 L of 1×PBS 
in a vial, followed by adding the E-tagged protein at appropriate molar ratio: GFP-En (1:3; 
250:750 nM ArgNPs/GFP-En); Cre-E10 (2:1; 250:125 nM ArgNPs/Cre-E10 ); GzmA-E10 
(1:2 250:500 nM ArgNPs/GzmA-E10); H2A-E10 (1:3; 250:750 nM ArgNPs/H2A-E10), 
Prothymosin- (1:3; 250:750 nM ArgNPs/PTMA). The assemblies were incubated at room 
temperature for another 10 min. Following the incubation, DMEM was added to the 
assemblies to make the final volume up to 1000 L. The nanoassemblies were then 
immediately added to cells grown overnight in round bottom confocal dish plates for 
delivery experiments. 
Cell culture. 80-100k cells were grown in a 24-well plate in low glucose DMEM 
(with 10% FBS, and 1% antibiotics) for overnight at 37 °C under 5% CO2. Cells were 
washed with 1×PBS (twice) before incubation with nanoassemblies. For confocal studies, 
~240,000 cells were seeded per dish. 
Delivery. Assembled E-tagged protein:ArgNPs nanoassemblies (preassembled in 
100 L PBS for 10 min, plus 400 L media for 24 well plate or 900 L media for confocal 
dish) were immediately transferred to confluently grown cells. Cells were then incubated 
with nanoassemblies at 37 oC and 5% CO2 for 3 h. Delivery efficiency was determined by 
Confocal microscopy or flow cytometry when necessary.  
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Confocal microscopy and Time-lapse imaging. Confocal microscopy imaging was 
performed using either Zeiss 510 Meta laser scanning microscope or Nikon spinning disc 
microscope. Time-lapse real time video imaging was performed in the Nikon spinning disc 
microscope.  
Cre-lox system generation. Briefly, the plasmid was constructed by placing a 
dsRed-STOP fluorescent protein sequence between loxP recognition sites, and a GFP 
sequences downstream of it [loxP-dsRed(STOP)-loxP-GFP]. Active Cre can excise out the 
loxP genes which will turn the color to GFP. 
Assessing Cre recombinase activity. Human embryonic kidney (HEK) cells were 
transiently transfected with Retroviral loxP-DsRed-STOP-loxP-GFP system to create a 
testbed for Cre recombinase activity. 48 h after the transfection, Cre-E10 was delivered 
into these cells using nanoassemblies. Cells were let grow for another 72 h, then used 
confocal microscopy or flow cytometry to assess the Cre activity by checking GFP positive 
cells. 
Assessing GzmA activity. After GzmA-E10 delivery, cells were incubated for 
another 3, 12, 24, or 48 h. Phosphatidylserine (PS) staining was performed in these cells 
according to standard manufacturer’s protocol. Further, caspase 3/7 activity assay was 
performed to assess GzmA-E10 activity in the delivered cells according to manufacturer’s 
protocol. 
Cholesterol depletion. To investigate the delivery mechanism, endocytic and 
membrane fusion inhibitors were used. Cells were pretreated with endocytic inhibitor 
[wortmannin (100ng/mL), chlorpromazine (g/mL)], and membrane fusion inhibitor 
[methyl-β-cyclodextrin (MBCD, 5mg/mL)] for 1 h, as reported previously.35 At the same 
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time nanoassemblies were prepared and kept ready. Inhibitor-treated cells were washed 
with 1×PBS twice, then the nanoassembly solutions were immediately applied to the cells 
for protein delivery. Confocal microscopy or flow cytometry experiments were performed 
after 3 h of nanoassembly incubation. 
 
4.5. Supporting figures 
 
Figure 4. 7. Characterization of nanoassemblies. TEM image of a) ArgNPs, and b) GFP-
E10:ArgNPs assemblies. c) DLS size measurement of ArgNPs, indicating the hydrodynamic size 
(~10 nm in diameter).  
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Figure 4. 8. E-tag length determines GFP-En delivery efficiency. a) Addition of appropriate En to 
GFP and their net negative charge. b) Flow cytometric assessment showing the GFP-En delivery 
efficiency as the length of E-tag was changed (also see Figure 4.2d for quantification). 
 
 
 
Figure 4. 9. [ArgNP]/[GFP-E10] ratio determines delivery efficiency. Flow cytometry data 
showing the ratio dependent GFP-E10 delivery efficiency. 
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Figure 4. 10. Confocal microscopy Z-stacking images showing thorough cytosolic and nuclear 
delivery of GFP-E10. Images were taken at every 1 micron interval. ‘0’ m indicates the bottom 
of the cell (at the dish surface). 
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Figure 4. 11. Comparison of protein delivery using various delivery strategies. While 
supercharged GFP and cell penetrating peptide (CPP) based protein-delivery suffer from 
endosomal entrapment, our E-tag based nanoassembly method delivers proteins directly to the 
cytosol.  
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Figure 4. 12. 3D reconstruction of cells from z-stacking confocal images showing GFP-E10 
delivery into the whole cell in different cell lines. Note that individual z-stacking images showed 
thorough cytosolic distribution of GFP-E10 (data not shown here). 
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Figure 4. 13. A membrane fusion like mechanism is involved in protein delivery. Confocal 
microscopy and flow cytometry show that endocytic inhibitors (wortmannin) did not block GFP-
E10 delivery, whereas membrane fusion inhibitor (MBCD) completely blocked delivery. 
 
 
Figure 4. 14. Membrane fusion, but not membrane puncture is involved in nanoassembly-
mediated protein delivery. Assembled GFP-E10 was delivered into cells in the presence of free 
mCherry protein in the media. Free mCherry protein did not enter the cell, while GFP-E10 was 
delivered into the cell through nanoassembly fusion. 
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Figure 4. 15. Delivered GzmA-E10 kills cells in a caspase 3/7 independent manner. Although 
GzmA-E10 delivery resulted in efficient cell death 24 h after delivery, the mechanism of cell death 
was caspase 3/7 independent; whereas, staurosporine caused caspase 3/7 dependent cell death in 
less than 3 h. Caspase 3/7 activation was measured using a standard fluorogenic peptide substrate.  
 
  
85 
 
 
4.6. References
(1) Mitragotri, S.; Burke, P. A.; Langer, R. Overcoming the Challenges in Administering 
Biopharmaceuticals: Formulation and Delivery Strategies. Nat. Rev. Drug. Discov. 2014, 
13, 655-672. 
(2) Gu, Z.; Biswas, A.; Zhao, M.; Tang, Y. Tailoring Nanocarriers for Intracellular Protein 
Delivery. Chem. Soc. Rev. 2011, 40, 3638-3655.  
(3) Komor, A. C.; Badran, A. H.; Liu, D. R. CRISPR-Based Technologies for the 
Manipulation of Eukaryotic Genomes. Cell 2017, 168, 20-36.  
(4) Mout, R.; Ray, M.; Lee, Y.W.; Scaletti, F.; Rotello, V. M. In Vivo Delivery of 
CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges. Bioconjug. Chem. 
2017, 28, 880-884. 
(5) Khalil, A. S.; Collins, J. J. Synthetic Biology: Applications Come of Age. Nat. Rev. 
Genet. 2010, 11, 367-379. 
(6) Leader, B.; Baca, Q. J.; Golan, D. E. Protein Therapeutics: A Summary and 
Pharmacological Classification. Nat. Rev. Drug. Discov. 2008, 7, 21-39. 
(7) Walsh, G. Biopharmaceutical Benchmarks 2014. Nat. Biotechnol. 2014, 32, 992-1000. 
(8) Stewart, M. P.; Sharei, A.; Ding, X.; Sahay, G.; Langer, R.; Jensen, K. F. In Vitro and 
Ex Vivo Strategies for Intracellular Delivery. Nature 2016, 538, 183-192. 
(9) Gilleron, J.; Querbes, W.; Zeigerer, A.; Borodovsky, A.; Marsico, G.; Schubert, U.; 
Manygoats, K.; Seifert, S.; Andree, C.; Stöter, M.; Epstein-Barash, H.; Zhang, L.; 
Koteliansky, V.; Fitzgerald, K.; Fava, E.; Bickle, M.; Kalaidzidis, Y.; Akinc, A.; Maier, 
M.; Zerial, M. Image-Based Analysis of Lipid Nanoparticle-Mediated siRNA Delivery, 
Intracellular Trafficking and Endosomal Escape. Nat. Biotechnol. 2013, 31, 638-646. 
(10) Fu, A.; Tang, R.; Hardie, J.; Farkas, M. E.; Rotello, V. M. Promises and Pitfalls of 
Intracellular Delivery of Proteins. Bioconjug. Chem. 2014, 25, 1602-1608. 
(11) Erazo-Oliveras, A.; Najjar, K.; Dayani, L.; Wang, T. Y.; Johnson, G. A.; Pellois, J. P. 
Protein Delivery into Live Cells by Incubation with an Endosomolytic Agent. Nat. 
Methods. 2014, 11, 861-867. 
(12) D'Astolfo, D. S.; Pagliero, R. J.; Pras, A.; Karthaus, W. R.; Clevers, H.; Prasad, V.; 
Lebbink, R. J.; Rehmann, H.; Geijsen, N. Efficient Intracellular Delivery of Native 
Proteins. Cell 2015 161, 674-690. 
(13) Han, X.; Liu, Z.; Jo, M. c.; Zhang, K.; Li, Y.; Zeng, Z.; Li, N.; Zu, Y.; Qin, L. CRISPR-
Cas9 Delivery to Hard-to-Transfect Cells via Membrane Deformation. Sci. Adv. 2015, 1, 
e1500454. 
 
86 
 
 
(14) Yang, X. C.; Samanta, B.; Agasti, S. S.; Jeong, Y.; Zhu, Z. J.; Rana, S.; Miranda, O. 
R.; Rotello, V. M.  Drug Delivery Using Nanoparticle-Stabilized Nanocapsules. Angew. 
Chem. Int. Ed. 2011, 50, 477-481. 
(15) Tang, R.; Kim, C. S.; Solfiell, D. J.; Rana, S.; Mout, R.; Velázquez-Delgado, E. M.; 
Chompoosor, A.; Jeong, Y.; Yan, B.; Zhu, Z. J.; Kim, C.; Hardy, J. A.; Rotello, V. M. 
Direct Delivery of Functional Proteins and Enzymes to the Cytosol using Nanoparticle-
Stabilized Nanocapsules. ACS Nano 2013, 7, 6667-6673. 
(16) Ray, M.; Tang, R.; Jiang, Z.; Rotello, V. M. Quantitative Tracking of Protein 
Trafficking to the Nucleus using Cytosolic Protein Delivery by Nanoparticle-Stabilized 
Nanocapsules. Bioconjug. Chem. 2015, 26, 1004-1007. 
(17) Tang, R.; Jiang, Z.; Ray, M.; Hou, S.; Rotello, V. M. Cytosolic Delivery of Large 
Proteins using Nanoparticle-Stabilized Nanocapsules. Nanoscale 2016, 8, 18038-18041. 
(18) Mout, R.; Tonga, G. Y.; Wang, L.-S.; Ray, M.; Roy, T.; Rotello, V. M. Programmed 
Self-Assembly of Hierarchical Nanostructures through Protein-Nanoparticle Co-
Engineering. ACS Nano 2017, 11, 3456-3462. 
(19) Mout, R.; Ray, M.; Tonga, G. Y.; Lee, Y.-W.; Tay, T.; Sasaki, K.; Rotello, V. M. 
Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. 
ACS Nano, 2017, 11, 2452-2458. 
(20) Cronican, J. J.; Thompson, D. B.; Beier, K. T.; McNaughton, B. R.; Cepko, C. L.; Liu, 
D. R. Potent Delivery of Functional Proteins into Mammalian Cells In Vitro and In Vivo 
using a Supercharged Protein. ACS Chem. Biol. 2010, 5, 747-752. 
(21) González-Toro, D. C.; Ryu, J. H.; Chacko, R. T.; Zhuang, J.; Thayumanavan, S. 
Concurrent Binding and Delivery of Proteins and Lipophilic Small Molecules 
Using Polymeric Nanogels. J. Am. Chem. Soc. 2012, 134, 6964-6967.  
(22) Dingwall, C.; Laskey, R. A. Protein Import into the Cell Nucleus. Annu. Rev. Cell 
Biol. 1986, 2, 367-390. 
(23) Jamur, M. C.; Oliver, C. Permeabilization of Cell Membranes. Methods Mol. Biol. 
2010, 588, 63-66. 
(24) Jiang, Y.; Tang, R.; Duncan, B.; Jiang, Z.; Yan, B.; Mout, R.; Rotello, V. M. Direct 
Cytosolic Delivery of siRNA Using Nanoparticle-Stabilized Nanocapsules. Angew. Chem. 
Int. Ed. Engl. 2015, 54, 506-510. 
(25) Gomez-Marquez, J.; Rodríguez, P. Prothymosin Alpha is a Chromatin-Remodelling 
Protein in Mammalian Cells. Biochem. J. 1998, 333, 1-3. 
(26) Tsien, R. Y. The Green Fluorescent Protein. Annu. Rev. Biochem. 1998, 67, 509-544. 
(27) Lieberman, J. The ABCs of Granule-Mediated Cytotoxicity: New Weapons in the 
Arsenal. Nat. Rev. Immunol. 2003, 3, 361-370. 
87 
 
 
(28) Nagy, A. Cre Recombinase: The Universal Reagent for Genome Tailoring. Genesis 
2000, 26, 99-109. 
(29) Bönisch, C.; Hake, S. B. Histone H2A Variants in Nucleosomes and Chromatin: More 
or Less Stable. Nucleic Acids Res. 2012, 40, 10719-10741.  
(30) Koo, B. K.; Stange, D. E.; Sato, T.; Karthaus, W.; Farin, H. F.; Huch, M.; van Es, J. 
H.; Clevers, H. Controlled Gene Expression in Primary Lgr5 Organoid Cultures. Nat. 
Methods 2011, 9, 81-83. 
(31) Martinvalet, D.; Dykxhoorn, D. M.; Ferrini, R.; Lieberman, J. Granzyme A Cleaves a 
Mitochondrial Complex I Protein to Initiate Caspase-Independent Cell Death. Cell 2008, 
133, 681-692. 
(32) Restifo, N. P.; Dudley, M. E.; Rosenberg, S. A. Adoptive Immunotherapy for Cancer: 
Harnessing the T Cell Response. Nat. Rev. Immunol. 2012, 12, 269-281. 
(33) Lieberman, J. Granzyme A Activates Another Way to Die. Immunol. Rev. 2010, 235, 
93-104. 
(34) Chowdhury, D.; Lieberman, J. Death by a Thousand Cuts: Granzyme Pathways of 
Programmed Cell Death. Annu. Rev. Immunol. 2008, 26, 389-420. 
(35) Saha, K.; Kim, S. T.; Yan, B.; Miranda, O. R.; Alfonso, F. S.; Shlosman, D.; Rotello, 
V. M. Surface Functionality of Nanoparticles Determines Cellular Uptake Mechanisms in 
Mammalian Cells. Small 2013, 9, 300-305. 
 
88 
 
CHAPTER 5 
DIRECT CYTOSOLIC DELIVERY OF CRISPR/CAS9-
RIBONUCLEOPROTEIN FOR EFFICIENT GENE EDITING 
 
 
5.1. Introduction 
Bacterially derived CRISPR system (Clustered Regularly Interspaced Short 
Palindromic Repeat) is a versatile tool for genome editing,1,2 transcriptional control of 
genes,3,4 and visualizing genome dynamics.5 Due to its genome editing efficiency, 
CRISPR/Cas9 system holds promises for curing human genetic diseases, as demonstrated 
through correction of a variety of disease-causing mutations in cultured cells6 and in animal 
models.7 These studies used gene delivery strategies to generate Cas9 inside cells. 
However, the required CRISPR genes stay in the host cells once delivered, causing 
unwanted gene editing and thus posing a major concern for CRISPR/Cas9 based gene 
therapy.8-10 Additionally, the constitutive expression of Cas9 gene in the host may elicit 
immunogenic response, making CRISPR gene therapy less practical for therapy.9,11 
Delivery of Cas9 protein along with a guide RNA (sgRNA) (Cas9-
ribonulceoprotein, or Cas9-RNP) provides an alternative strategy for CRISPR process, 
offering a transient way of editing genes. Although a few strategies for Cas9 protein 
delivery have been reported,12-15 these strategies suffer from endosomal entrapment of both 
Cas9 and sgRNA. Mechanical methods including electroporation16,17 and membrane 
deformation18 provide direct delivery, however they require specialized processing and are 
generally impractical for in vivo therapeutic applications.  
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Here, we report a highly efficient editing strategy based on co-delivery of Cas9 
protein and sgRNA into cells. This approach uses gold nanoparticles to co-assemble with 
engineered Cas9 protein and sgRNA into nanoassemblies. These vectors deliver protein 
and nucleic acid efficiently to the cytoplasm, with concomitant transport to the nucleus. 
Using this approach we achieved up to ~90% delivery efficiency in a range of cell types, 
with subsequent gene editing efficiency up to 30%. 
 
5.2. Results  
Co-engineering of Cas9 protein and gold nanoparticles. We first engineered Cas9 
protein for self-assembly with the cationic arginine gold nanoparticles (ArgNPs) (Figure 
5.1).19 Cas9 is a highly positively charged protein, so a glutamate peptide tag (E-tag)20 was 
inserted at the N-terminus of Streptococcus pyogenes (Sp) Cas9 protein. We engineered a 
series of Cas9 proteins having a variable E-tag (En) length, where n= 0, 5, 10, 15, and 20. 
Notably, a Cas9 protein with no modification (Cas9E0) possesses a net 20 positive charges, 
however, insertion of the E-tag provided a patch of local negative charges that presumably 
enabled interaction with the positively charged ArgNPs.21 In addition, a nuclear 
localization signal (NLS) was inserted to the C-terminus to provide nuclear targeting of 
Cas9.  
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Figure 5. 1. Rational engineering of Cas9 protein and arginine nanoparticles (ArgNPs) for 
intracellular delivery of Cas9 protein or Cas9-RNP via membrane fusion. (a) Engineering Cas9 to 
carry an N-terminus E-tag and a C-terminus nuclear localization signal (NLS). (b) Chemical 
structure of ArgNPs. (c) Schematic showing nanoassembly formation by Cas9En-RNP and 
ArgNPs. (d) Delivery of Cas9En via membrane fusion mechanism. Fusion of nanoassemblies to 
the cell membrane may facilitate direct release of the protein payload into cytoplasm, bypassing 
endosomes. 
 
Fabrication of Cas9En-ArgNP nanoassemblies. Having engineered and purified 
Cas9En proteins, we focused on fabricating self-assemblies between Cas9En and ArgNPs. 
When the E-tagged Cas9En protein or Cas9En-RNP were mixed with ArgNPs, they formed 
self-assembled nanoassemblies (Figure 5.1). These nanoassemblies are designed to fuse to 
cell membranes upon contact, releasing encapsulated Cas9En or Cas9En-RNPs directly 
into the cell cytoplasm (Figure 5.1), and eventually to the nucleus. The desired self-
assemblies were fabricated by mixing Cas9En or Cas9En-RNPs and ArgNPs at varying 
molar ratio in cell culture DMEM media.20 Following this step, we characterized the 
assemblies after incubating the mixture at room temperature for 10 min. Transmission 
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electron microscopic (TEM) results indicated the formation of nanoassemblies. As the 
length of E-tag increased, larger sized assemblies were observed reaching 475 (±60) nm in 
diameter (Figure 5.2). The resulting large size of the assemblies compared to the individual 
ArgNPs (~10 nm hydrodynamic diameter), Cas9En (~7.5 nm hydrodynamic diameter), and 
sgRNA (5.5 nm) (Figure 5.6) indicated the incorporation of a large number of nanoparticles 
and proteins into the self-assembled structures. Interestingly, high resolution TEM image 
indicated the dense packing of granular proteins into the nanoassemblies (Figure 5.2b). 
Cas9E20-RNPs also formed similar nanoassemblies with ArgNPs, however, additional 
aggregates were observed (Figure 5.2a). The optimal working molar ratio for assembly 
fabrication was found to be 2:1 (ArgNP:Cas9En), as determined from subsequent delivery 
experiments. These results collectively indicated that the length of E-tag, hence the 
multivalency, plays a crucial role in the self-assembly formation between engineered 
Cas9En and ArgNPs. 
 
Figure 5. 2. Nanoassembly formation between ArgNPs and Cas9En or Cas9En-RNP is dictated by 
E-tag length. (a) TEM images of nanoassemblies. As the length of E-tag increased, larger 
nanoassemblies formed that are favorable for intracellular delivery of Cas9En (Figure 5.3). (b) 
High magnification image of nanoassemblies showing the inner structure containing protein and 
nanoparticle granules. 
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Direct cytoplasmic delivery of Cas9En protein using nanoassemblies. We next 
investigated the protein delivery capability of these nanoassemblies. We fabricated 
assemblies of ArgNPs with Cas9En or Cas9En-RNPs and incubated with HeLa cells in 
cultured media. Cas9En were labelled with fluorescein isothiocyanate (FITC) to monitor 
the cellular uptake efficiency. Delivery efficiency was evaluated after 3 h of incubation 
using confocal laser scanning microscopy (CLSM). Cytoplasmic delivery efficiency of 
Cas9En gradually increased as the E-tag length increased from E0 to E20, achieving up to 
Cas9E20 delivery in 90% of the cells (Figure 5.3a, b; Figure 5.7). Delivered Cas9En readily 
dispersed into cytoplasm, and reached the nucleus, a requirement for gene editing (Figure 
5.3c). Confocal microscopy Z-stacking further supported the cytoplasmic and nuclear 
localization of the delivered payload (Figure 5.8). Additionally, delivered Cas9En proteins 
stayed in the cells for at least 30h, without hampering the cell growth and viability (Figure 
5.9). It is possible that poor cytoplasmic delivery of Cas9En with shorter length of E-tag, 
i.e. Cas9E0, Cas9E5, and Cas9E10, may be attributed to their inadequate nanoassembly 
formation with ArgNPs (Figure 5.2a). Likewise, Cas9E20-RNP was also delivered into 
cells, although to a lesser extent compared to Cas9E20 alone (Figure 5.3a). Interestingly, 
Cas9En with a shorter E-tag (E0 and E5) was found to bind the cell membrane, presumably 
due to the presence of unbound positively charged Cas9 protein in the assembly solution, 
which alone is capable of binding to the cell membrane (Figure 5.10). The delivery was 
further validated in other cell lines including human embryonic kidney cells (HEK-293T), 
and mouse macrophage (Raw 264.7) cells (Figure 5.11). Collectively, these results 
demonstrated the importance of co-engineering of the protein and ArgNPs for effective 
Cas9 delivery.  
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We performed time lapse video imaging to study the intracellular release-dynamics 
of Cas9En. We recorded the video at 30s intervals 1h after the addition of the 
nanoassemblies into HeLa cells. Cas9E20 delivery was nearly complete in cultured cells 
after 3h of post incubation (Figure 5.12). Real time tracking of a delivery event revealed a 
remarkably fast intracellular delivery, requiring only minutes for complete 
cytoplasmic/nuclear delivery after the initial contact by a nanoassembly (Figure 5.3d). 
Notably, a slight delay (1-2 min) in Cas9E20 transport into the nucleus from the cytosol 
was observed, presumably due to active nuclear transport of NLS-tagged Cas9En (Figure 
5.3d). The instantaneous release of Cas9E20 into the whole cell further suggested that the 
payload may be directly released from the cell membrane and did not go through 
endocytosis.  
94 
 
 
Figure 5. 3. Endosomal entrapment-free direct cytoplasmic/nuclear delivery of engineered Cas9En 
or Cas9En-RNP is dictated by E-tag length. (a) Cytoplasmic/nuclear delivery of FITC labelled 
Cas9En increased as the length of E-tag increased, reaching maximum at E20. (b) Percentage 
cytoplasmic/nuclear delivery efficiency of Cas9En as measured by confocal microscopy. (c) 
Distribution of delivered Cas9E20 protein inside the cell, showing preferential accumulation of the 
protein in the cytoplasm and nucleus. (d) Real time tracking of a delivery event. Time lapse imaging 
of Cas9En delivery showed Cas9E20 was rapidly released into the cytosol and subsequently to the 
nucleus following a nanoassembly (red arrow) made contact with the cell surface. Zero second (00 
s) represents the beginning of the delivery event. 
 
Mechanism of CRISPR/Cas9 delivery. We investigated the mechanistic details of 
nanoassembly mediated Cas9-ribonucleoproteins delivery into cells. Nanoparticle 
mediated biomolecular delivery can occur through either an endocytic or a membrane 
fusion mechanisms (Figure 5.1d).22 We pretreated HeLa cells with inhibitors of 
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endocytosis (chlorpromazine and wortmannin) or cholesterol-dependent membrane fusion 
(methyl-beta-cyclodextrin (MBCD)),23 to investigate whether similar mechanisms are 
involved in Cas9En-RNP delivery. After the inhibitor treatment, HeLa cells were incubated 
with the nanoassemblies, and monitored the delivery by CLSM. As shown in Figure 5.4, 
MBCD treatment inhibited FITC-Cas9E20 delivery into cells (2% delivery), compared to 
chlorpromazine (CPM) (83%) and wortmannin (79%), and untreated controls (90%). These 
studies collectively suggested that the nanoassembly-mediated Cas9En-RNP delivery 
occurred preferably through a cholesterol dependent membrane fusion-like process, but not 
via cellular endocytosis. Thus, our approach provided a direct transfer of Cas9En-RNP 
across the cell membrane into the cytoplasm resulting in a remarkably high delivery 
efficiency. 
 
Figure 5. 4. A cholesterol dependent membrane fusion-like delivery mechanism is involved in 
nanoassembly-mediated Cas9En-RNP delivery. (a) cholesterol depletion (MBCD treatment) 
completely inhibited FITC-Cas9E20 delivery, whereas endocytic inhibitors (b) chlorpromazine 
(CPM) and (c) wortmannin did not block the delivery significantly. (d) Percentage of Cas9E20 
cytoplasmic/nuclear delivery after various inhibitors treatment. 
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Gene editing in CRISPR/Cas9 delivered cells. Having efficiently delivered 
engineered Cas9En protein or Cas9En-RNP into cells, we evaluated the gene editing 
capability of this construct. We assembled Cas9E15-RNP with ArgNPs targeting human 
AAVS1 gene and delivered these nanoassemblies into the HeLa cells.24 In these 
experiments, the nanoassemblies were incubated with the cells for 3 h. in serum-free media; 
suitable conditions for in vitro and ex vivo applications.  Genome editing efficiency was 
evaluated after 48 h, using indel (insertion and deletion) analysis.27 As evident from Figure 
5.5, targeting AAVS1 gene resulted up to 29% of indel efficiency. As expected, delivering 
Cas9E15-RNP alone, or the untreated controls did not result in gene editing. To validate 
the usability of our method for any gene, we further targeted the human PTEN gene with 
an appropriate sgRNA.25 Likewise, targeting PTEN gene resulted up to 30% of indel 
efficiency. The gene editing was further validated in HEK-293T and Raw 264.7 cell lines 
(Figure 5.13). These results collectively showed the efficient genome editing capability of 
our methodology.  
 
Figure 5. 5. Efficient gene editing resulted from Cas9En-RNP delivery. (a) Delivery of Cas9E15-
RNP to target AAVS1 and PTEN gene in HeLa cells resulted efficient gene editing, as determined 
by indel (insertion and deletion) assay: Lane 1: Cas9E15-RNP:ArgNPs, 2: Cas9E15-RNP, and 3: 
cells only. Indel efficiency is given in percentage. 
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5.3. Conclusions 
  In summary, we present here an engineering approach to drastically enhance the 
cytoplasmic/nuclear delivery of Cas9-RNPs, with concomitantly effective gene editing. 
This system provides a direct platform for multiple in vitro applications, and will greatly 
facilitate research in many other areas of rapidly growing genome engineering including 
spatiotemporal control of gene transcription and imaging chromatin dynamics. 
Additionally, this system provides a starting point for the creation of transient gene editing 
therapeutics without the requirement for gene delivery.  
 
5.4. Experimental section  
Engineering E-tagged Cas9En. Glutamic acid tag (E-tag) was inserted to N-
terminus of SpCas9 through site directed mutagenesis (SDM). Briefly, following primers 
were used for the insertion of E-tag (inserted nucleotides are underlined in the primers) 
into the N-terminus Cas9 using pET28b-Cas9 expression vector (Addgene plasmid id= 
47327)26 as the template. Note that the C-terminus of Cas9 contained a nuclear localization 
signal (NLS) and a 6xHis tag. 
Cas9E0- F: ATGGACAAGAAGTACTCCATTGGGCTCGATATCGGC 
Cas9E0- R: GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG 
Cas9E5- F: ATGGACAAGAAGTACTCCATTGGGCTCGATATCGGC 
Cas9E5- R: 
CTCTTCCTCCTCCTCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTT
CTAGAGGGG 
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Cas9E10- F: 
ATGGAGGAAGAAGAGGAAGAGGAGGAGGAAGAGATGGACAAGAAGTACTC
CATTGGGCTCGAT 
Cas9E10- R: GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG 
Cas9E15- F: (Cas9E10 as template) 
ATGGAAGAGGAGGAAGAAGAGGAAGAAGAGGAAGAGGAGGAGGAAGAGAT
GGAC 
Cas9E15- R: GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG 
Cas9E20- F: (Cas9E15 as template) 
ATGGAAGAAGAGGAGGAAGAAGAGGAGGAAGAAGAGGAAGAAGAGGAAGA
GGAGGAG 
Cas9E20- R: GGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGGG  
 Recombinant proteins (Cas9En) were expressed in E. coli BL21 Rosetta strain 
using standard protein expression protocol. Briefly, protein expression was carried out in 
2xYT media with an induction condition of 0.75 mM IPTG and 18 oC for 16 hours. At this 
point, the cells were harvested and the pellets were lysed by using 1% Triton-X-
100/DNase-I treatment. Triton-X-100 treatment was performed for ~30 min followed by 
DNase-I treatment for 15 min. Lysed cells were then spun down at 14,000 rpm for 30 min. 
The supernatant was collected and to it an additional 150 mM salt was added.20 Proteins 
were purified using HisPur cobalt columns. Proteins were finally preserved in PBS buffer 
containing 300 mM salt. The purity of native proteins was determined using 8% SDS-
PAGE gel. 
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sgRNA design and synthesis. sgRNAs were in vitro transcribed from dsDNA 
template (containing the protospacer and the tracRNA sequence) using AmpliScribe-T7-
Flash Transcription kit according to manufacturer’s protocol. dsDNA was PCR amplified 
from a template plasmid carrying the tracRNA sequence.27 The following primers were 
used for the PCR amplification. 
sgRNA-R: AAAAAAGCACCGACTCGGTGCCACT (common for all) 
sgAAVS1-F: 
GAAATTAATACGACTCACTATAGGctccctcccaggatcctctcGTTTTAGAGCTAGAA
ATAGCA 
sgPTEN-F: 
GAAATTAATACGACTCACTATAGGgagatcgttagcagaaacaaaGTTTTAGAGCTAGA
AATAGCA 
In vitro transcribed sgRNAs were purified using RNA purification kit (Zymo 
research RNA Clean & Concentrator). 
Nanoparticle synthesis and characterization. Arginine-functionalized gold 
nanoparticles (ArgNPs) were prepared according to our previous methods.19 The arginine-
functionalized thiol ligand was synthesized first. Following this, ArgNPs were prepared by 
conventional place-exchange reaction of 2-nm sized 1-pentanethiol-protected gold 
nanoparticles (Au-C5) with HS-C11-TEG-NH-Arginine. The resultant ArgNPs were 
dissolved in distilled water, purified by dialysis, and whose characterization was reported 
previously.19,20 Complete synthesis of a batch of ArgNPs takes around 1-2 weeks, however 
can be synthesized in large batches that may be stable and used for years for delivery 
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purpose. The manufacturing cost of our gold nanoparticle is roughly ~10-20 cents (USA) 
per sample of ‘delivery’. 
Nanoassembly fabrication. Cas9En-RNP:ArgNPs nanoassemblies were prepared 
through a simple mixing procedure. Cas9En and sgRNAs (1:1 molar ratio)28 were 
assembled in 1×PBS for 30 min at room temperature first, then ArgNPs (50 M stock in 5 
mM PB, pH 7.4) were added to 100 L of 1×PBS in another vial, followed by adding the 
preassembled Cas9En-RNP at appropriate working molar ratio [usually at 2:1 ratio 
(ArgNP, 125 nM)/(Cas9En-RNP, 62 nM), which corresponds to ~10 g of Cas9En protein 
and ~2 g of sgRNA per cultured dish]. The working molar ratio was determined by 
screening different ratios in the subsequent delivery experiments. The nanoassemblies 
were incubated at room temperature for another 10 min. DMEM was added to the 
nanoassemblies to make the final volume up to 1000 L. The nanoassemblies were then 
incubated either at 37 °C for 30 min for TEM, or directly added to cells grown overnight 
in confocal dish for delivery experiments. 
Cell culture. 240,000-300,000 cells were grown in a confocal dish (glass bottom 
culture dishes, MatTek) in DMEM (with 10% FBS, and 1% antibiotics) for overnight at 37 
°C under 5% CO2. Cells were washed with 1×PBS (twice) before incubation with 
nanoassemblies.  
Delivery. Assembled Cas9En-RNP:ArgNPs nanoassemblies (preassembled in 100 
L PBS for 10 min, plus 900 L DMEM media) were immediately transferred to each dish 
of confluently grown cells. Cells were then incubated at 37 oC and 5% CO2 for 3h. At this 
point cells were washed with 1xPBS buffer and immediately processed for investigating 
delivery efficiency that was determined by Confocal microscopy (Zeiss LSM 510 Meta 
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microscope, or Nikon A1 laser scanning microscope). Z-stacking was performed using 
Nikon A1, at every 125 nm interval. 
 It is noteworthy that the nanoassemblies can be incubated with cells for a longer 
period of time (~24h) without affecting cell growth/viability, an important issue for in vitro 
and ex vivo editing. 
Estimation of cytoplasmic/nuclear delivery efficiency. Since flow cytometry cannot 
distinguish between cytoplasmic/nuclear delivery and endosomally-entrapped delivery, we 
used confocal microscopy to estimate the delivery efficiency. Around 400 cells were 
counted for each Cas9En, 3h after the delivery as described above. 
Time lapse video imaging. Live-delivery imaging was performed using confocal 
microscope. Briefly, 1h after the nanoassemblies were added to the cultured HeLa cells in 
a live-cell imaging chamber containing humidified 5% CO2 at 37 
0C, the images were 
acquired at every 30s interval for 2h using 60x oil immersion lens.  
Cholesterol depletion. Endocytic and membrane fusion inhibitors were used to 
block the Cas9En-RNP delivery. Cells were pretreated with wortmannin (150ng/mL), 
chlorpromazine (g/mL), and methyl-β-cyclodextrin (MBCD, 7.5mg/mL) in DMEM 
media for 1 h at 37 oC and 5% CO2.
23 In the meantime, nanoassemblies were prepared. 
Inhibitor-treated cells were washed with 1×PBS twice, then the nanoassembly solutions 
were applied for Cas9En delivery. Confocal microscopy experiments were performed after 
3h of nanoassembly incubation to image and estimate cytoplasmic/nuclear delivery. 
Indel analysis. After Cas9E15-RNP delivery for 3h, cells were washed and replaced 
with DMEM media (with 10% FBS, and 1% antibiotics), then allowed to grow for another 
48 h. At this point cells were harvested to extract genomic DNA using QuickExtract 
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genomic DNA isolation kit (Epicentre biotechnologies). Indel assays were performed using 
T7 endonuclease-I according to standard protocol.27 
Cas9En protein sequence. (En at the N-terminus represents E-tag, where n = 0, 5, 
10, 15, and 20; NLS is underlined at the C-terminus) 
MEnMDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL
LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL
VEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAH
MIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARL
SKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTY
DDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDE
HHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEK
MDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNR
EKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIE
RMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKK
AIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIK
DKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYT
GWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQ
VSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARE
NQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGR
DMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEE
VVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQIT
KHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYH
HAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAK
YFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQ
VNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLV
VAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY
SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQK
QLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHL
FTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
SRADPKKKRKVAAALEHHHHHH 
 
 
103 
 
5.5. Supporting figures 
 
Figure 5. 6. TEM and DLS characterization of nanoparticles, Cas9 and sgRNA. (a) TEM of 
ArgNPs. Hydrodynamic size of ArgNPs (b), Cas9 (c), and sgRNA (d). 
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Figure 5. 7. E-tag length determines cytoplasmic/nuclear delivery of Cas9En. Laser scanning 
confocal microscopy (LSCM) images of delivered FITC labelled Cas9En proteins using 
nanoassemblies. Two representative slides are provided here for each Cas9En delivery. For 
quantitative estimation of cytoplasmic/nuclear delivery a large number of slides were considered, 
and at least ~400 cells were counted. Images were taken 3h post-incubation of the nanoassemblies 
with Hela cells. 
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Figure 5. 8. Confocal z-stacking images of delivered FITC labelled Cas9E20 revealing 
cytoplasmic/nuclear distribution of delivered Cas9. Above images were taken from every 1.25 
micron apart. 
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Figure 5. 9. Lifetime of delivered Cas9En. Delivered Cas9En remains in the cell for a long period 
(at least over a day), without affecting cell viability and growth. Confocal microscopy images 
showing delivered FITC-labelled Cas9En proteins after 30 h of delivery. Delivered Cas9En did not 
hamper the cell viability, as can be seen from the regular cell morphology in the bright field image. 
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Figure 5. 10. Cas9En protein alone get trapped in the endosomes. Confocal microscopy images 
showing Cas9En proteins, either attached to the cell membrane or trapped in the endosomes, after 
3 h incubation of the cells with Cas9En protein alone. 
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Figure 5. 11. Delivery of Cas9E20 into cultured cells. Confocal microscopy images showing 
delivered FITC-Cas9E20 after 3 h of incubation in human embryonic kidney cells (HEK-293T), 
and mouse macrophage (Raw 264.7).  
 
 
Figure 5. 12. Time-lapse video imaging of Cas9E20 delivery process. Alexa fluor 488 labeled 
Cas9E20 delivery was nearly completed in 3h. 
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Figure 5. 13. Gene editing in HEK-293T and Raw 264.7 cells. PTEN gene was targeted using 
Cas9E15-RNP with appropriate sgRNA in HEK293T and Raw 264.7 cells. 48h after delivery indel 
analysis was performed using standard procedure. (1) Cas9E15-RNP, and (2) cells only. Indel 
efficiency is given in percentage. 
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